INDEX

Note: Page numbers in italics refer to Figures; those in bold to Tables; those with (a) refer to appendices

AA priority (1987), 774
AADA, see Abbreviated Antibiotic Drug Application
AAP, see American Academy of Pediatrics
Abbreviated Antibiotic Drug Application (AADA), 755
Abbreviated New Drug Application, see ANDA, 753, 755, 805, 875
Absolute humidity, 268
Absorbance, 4, 5
Absorbed oral dose, 169
Absorption coefficient, 608
Absorption enhancers
  buccal, 463(a)
  ocular, 572, 573
  nasal, 441, 463(a)
  sublingual, 463(a)
  transderal, 615(a)
Absorptivity, 5, 6
Accelerated approval, 774–5, 789–90
Accelerated approval regulations (1992), 775
Accelerated stability testing, 86, 510
Acceleration due to gravity, 61, 81, 361–2, 493
Acceptance criteria, 292, 297, 353, 445–7, 772(a), 908
Accreditation Commission for Health Care (ACHC), 699
Accuracy, 50–51, 146, 382, 436, 526, 831, 888, 905(a)
Acetaminophen, 263, 729, 763
Acetylated monoglycerides, 280
Acetyltributyl citrate (ATBC), 280, 310(a)

Acetyltributyl citrate (ATEC), 311(a)
ACHC, see Accreditation Commission for Health Care
Acid dissociation constant, 7, 37
Acidifying agents
  acetic acid, 38, 551(a), 583(a)
  citric acid, 38, 442, 464(a), 555(a), 558(a)
  fumaric acid, 38, 314(a), 555(a)
  glacial acetic acid, 38, 583(a)
  hydrochloric acid, 29–30, 38, 442, 551(a)
  lactic acid, 38, 128, 500, 551(a), 631
  malic acid, 38
  nitric acid, 38
  phosphoric acid, 38
  propionic acid, 38
  sodium phosphate monobasic, 38
  sulfuric acid, 28, 29, 30, 38, 532, 583(a)
  tartaric acid, 38
Aclar, see polychlorotrifluoroethylene
Acoustic impedance, 607
Acoustic streaming, 608
Activation delivery techniques, 160
Active electrode, 602, 604
Active Ingredient Manufacturer (AIM), 822
Active Ingredients, 700, 753–4, 759, 887
Active substance (AS), 677, 817–8, 820–822, 916
Active Substance Manufacturer, 826

© 2013 John Wiley & Sons, Inc. Published 2013 by John Wiley & Sons, Inc.

947
Active Substance Master File, 820
Actual capability index, 340
Actual yield, 673
AcuForm, 632
Acute toxicity studies, 913
Acyclovir Sodium, 90, 601
Adaptive aerosol delivery, 426
ADE, see Adverse event experience report, 948
Adhesion tension, 59
Adhesives, 289, 427, 589, 590, 616(a)
Administrative information
amendments, 808
original submissions, 808
Adsorption, 65
affinity, 66
capacity, 66
chemisorption, 65
desorption, 65
multilayer formation, 65
physiosorption, 65
Adsorption affinity method, 67
Advancing regulatory science at FDA, 939–41
strategic plan for regulatory science, 939
Advantages and disadvantages
aerosols, 418
dry powder, 419
nebulizer, 423
pressurized metered dose inhalers, 423
capsules
hard shell, 321
soft shell, 343
disperse systems
emulsion, 361
microemulsion, 393
injectables, 469
modified release, 621
nasal, 439
ophthalmics, 565
running powder manufacturing, 223
tables, 216
transdermal, 588
AdvTab™ tablets, 164
Adverse event experience reporting, 792
Advil, 753
Aerodynamic diameter, 416, 428, 435, 452
Aerogen, 424–5
Aeroneb, 424–5
Aerosol product design
advantages and disadvantages, 418
advantages and disadvantages of aerosol nasal and mucosal systemic delivery, 439
advantages and disadvantages of conventional nebulizers, pressurized inhalers, and passive dry powder inhalers, 423
attribute tests, 451
container closure system design, 443
additional packaging, 443
critical secondary container, 443
final exterior package, 443
primary container, 443
regulatory submission information, 445
secondary container, 443
semipermeable, 444
Diskus inhaler, 435
dry powder inhalers, 128, 416, 433
active, 433
passive, 433
excipients, 463
extractables, 173, 191, 444–5
fine particle fraction, 416
inhalation drug delivery system, 415
leachables, 172, 444, 449
metered dose inhaler, 169, 173, 415, 417, 428
metered dose liquid inhaler, 462
metering valve, 428–9
nebulizers, 416, 422
electrohydrodynamic, 424
high pressure, 424
jet, 424
ultrasonic, 424
preformulation
solid state properties, 419
solution and chemical, 419
pressurized metered dose inhalers, 416, 432
propellants, 422
butane, 429
hydrofluoroalkanes, 429, 430
isobutane, 429
Respimat soft mist, 426
respirable dose, 432
risk management matrix for orally inhaled and nasal drug products, 447
spray
buccal, 167, 439
lingual, 439
nasal, 439
sublingual, 439
spray drying, 126
process analytical technology, 494
scale-up, 401
Turbohaler, 434
AERx, 167, 424, 426
AERx Insulin Diabetes Management System, 167
Affinity of the drug, 17
Agent or representative, 816
Aggregation, 37, 80, 128–9, 167–9, 363–4, 372, 378, 436, 490
Aggregation number, 387–8
AIDS, 131, 646, 773–4, 775, 777, 780, 927
Alatrofloxacin Mesylate, 90
Albuterol, 91, 162, 417, 430
Albuterol Sulfate, 91
Alcohol, USP calculations, 35–6
Aldehyde levels in commonly used capsule excipients, 356
Aldehyde levels in commonly used liquid-fill capsule excipients, 357
Allergenic ingredients, 710
Allopurinol, 91
Aluminum level, 532
AmBisome, 391, 479, 495
American Academy of Ophthalmology (AAO), 577
American Academy of Pediatrics, 782
American Chemical Society-certified, 710
American Colleges of Apothecaries, 720
American Pharmacists Association, 720
Aminocaproic Acid, 91
Amiodarone Hydrochloride, 91
Amount of emulsifier, 380, 382–3
Amphiphiles, 386–7, 389
Amphiphilic, 386–7, 390
Amphiphilic associations, 387
Amphotericin B, 91, 389, 391, 476–7, 479, 494–6
Analysis of variance, 49, 140, 144
Analytical procedure, 887–8
Anatomy of the eye, 561, 562
Anatomy of the skin, 589
ANDA, see Abbreviated New Drug Application,
Androgel, 595, 598
Anhydrous dicalcium phosphate, 330
Anhydrous Lactose, 306, 330
Animal Drug User Fee Act, 641
Animal efficacy rule requirement, 801
Animal pharmacology and toxicology studies, 737, 739
Animal testing, 729
Long term testing, 730
Short term testing, 729
Anionic starch microspheres, 68
Annealing, 508–9, 512, 514, 518
Annual Review, 831, 903, 926
Annual Update/Annual Reports (ARs), 816
Anodal delivery, 602
Antiadherants and antisticking agents, 230, 214(a)
Antimicrobial agents, 229, 324, 422, 450, 480, 485, 487, 531, 535, 552(a)
Antioxidants, 86, 312, 370, 424, 441, 475, 478, 481–5, 488–9, 534, 554(a), 567, 583, 605, 616(a)
APEC, see Asia-Pacific Economic Cooperation
API, see Active Pharmaceutical Ingredient
Apparent particle density, 435
Applicant (drug sponsor), 736
Application to Market a New Drug for Human Use, 745
Applied current, 603, 605
Appointee of an agent, 816
Approval letter, 749, 758
Approved drug products, 206(a), 221, 700, 753
Aquaphyton, 389
Aqueous humor, 563–4, 569
Arithmetic diameter, 122
Arrhenius model, 87, 89
ARS, see Advancing Regulatory Science
AS, see active substance
ASEAN, see Association of Southeast Asian Nations
Asia-Pacific Economic Cooperation (APEC), 650
ASM, see Active substance manufacturer
ASMF, see Active Substance Master File
Aspirin, 4, 5, 210(a), 477, 877, 880, 903(a)
Association colloids, 365, 367, 370, 377, 386–7
Association of Southeast Asian Nations (ASEAN), 650
ATBC (Acetyltributyl Citrate), 280, 310(a)
ATEC (Acetyltriethyl Citrate), 280, 311(a)
Atenolol, 92
Atropine Sulfate, 92, 568
Attention deficit/hyperactivity disorder (ADHD), 797
Attribute Test, 450
aerosols, 451
Attribute test(s), 403
aerosols inhaler, 450, 451
dry powder, 451
nebulizer, 451
pressurized metered dose inhalers, 451
capsules, 350
hard shell, 351
soft shell, 351
disperse system, 402, 468
macroemulsion, 404
suspension, 404
injectables, 535
modified release, 305
nasal, 450
ophthalmics, 577
running powder manufacturing process, 350–351
tablets, 293
transdermal, 209(a)
Auger filling, 335
Auto-Injector
Automatic, mechanical, and electronic equipment [Sec. 211.68], 658
Average particle size, 120
data projection techniques, 121
hydrodynamic diameter, 120
principal component analysis, 121
self-organizing maps, 121
volume-equivalent diameter, 120
Aztreonam, 415
Baclofen GRS, 161
Balanced salt solution (BSS), 577
Bar code label rule, 796
Basis of Design (BOD), 830
design consideration, 833
impact assessment, 834
Batch number, 676
Batch production and control records [Sec. 211.188], 673
Baye’s Rule, 145
BBB, 165
BBWs, see Black box warnings
BCS, see biopharmaceutical classification system
Class 1 drug compounds, 754
BDDCS, see biopharmaceutics drug disposition classification system
BE, see Bioequivalence
Beer’s Law, 5
Benzalkonium Chloride, 68, 316(a), 388, 442, 463(a), 553(a), 569, 571–3, 581(a)
Betoptic S suspension, 571
Benzoic Acid, 36–7
Best Pharmaceuticals for Children Act (BPCA), 641, 781
Bethanechol Chloride, 93
Beurer Nebulizer IH50, 424
Beyond-use dating, 86, 89, 90, 707–8, 713–4, 717–9, 726(a)
Binomial distribution population mean, 254
Binominal distribution, 254, 256
Biodhesive ophthalmic drug inserts (BODI), 574
Bioavailability, 45
Biodegradable carrier system, 51, 52
Biodyl, 705
Bioequivalence parameters, 47
Bioequivalence review, 756
Bioequivalent, 45
Biological equivalents, 45
Biologics Control Act, 639
Biologics license application (BLA), 759, 774
Biologics Price Competition and Innovation Act (BPCI Act), 759
Biopharmaceutical classification system (BCS), 52, 368, 754
Biopharmaceutical review, 746
Biopharmaceutics drug disposition classification system, 186, 228
Biosimilar drugs, 759
Biosimilar medicinal product, 759
Biosimilars, 753, 759
Biotechnology products, 69, 112, 125, 164, 167, 170, 536
BLA, see Biologics license application
Black box warnings, 802–3
Blending, 148, 189, 221, 243, 253, 256–7, 262, 334, 372, 493–4
Blinding clinical trials, 331
Blister assembly, 291
Blister laminates, 288, 290
Blister pack, 283–5, 288, 289, 291, 292, 296
Blister strips, 289
Blood brain barrier, 165
Blow fill seal, 151, 427
BMS, see Building management system
Body surface area conversion factor (BSA-CF), 932
Boltzmann’s constant, 593
Boric acid, 33, 582(a)
1.9% solution, 33
Bovine spongiform encephalopathy, 319, 323, 711
BP, see British Pharmacopeia
BPCA, see Best Pharmaceuticals for Children Act
BPCI Act, see Biologics Price Competition and Innovation Act
Bracketing, 296, 455, 856, 891
Brand name, 49, 753–4
Braunauer Emmet & Teller, 66
British Pharmacopeia, 895
Brittle fracture, 246–9, 263–4, 275
Brinzolamide suspension, 569, 570
Brompheniramine, 93
Brompheniramine Maleate, 93
BSA-CF, see Body surface area conversion factor
BSE, see Bovine spongiform encephalopathy
Bubble point, 529–30
BUD, see Beyond-use-date
Buffers, 7, 369–70, 411, 474–5, 479–80, 532, 551(a), 564, 567
Buffer capacity, 7, 8, 424, 480, 485, 562, 567
Buffer solution, 7
total buffer concentration, 7
Building Management System (BMS), 856
Bulk active ingredients, 700
Bulk density, 124, 126–7, 167, 221, 226, 246, 258, 329, 331, 366, 419, 470
Bulk erosion, 623
Bulk product, 623
Bupropion HCl monolithic coated, 625
Bureau of Alcohol, Tobacco, Firearms and Explosives, 643
Bureau of Chemistry, 639
C & Q, see Commissioning and Qualification
CFR, see Code of Federal Regulations
Cake characterization, 509
Calan melt-extrusion, 629
Calcitonin, 168, 442, 919
Calcium sulfate dihydrate, 307(a), 330
Calculation of yield [Sec. 211.103], 662
CAPA, see Corrective action and preventative action
Capillary type viscometers, 77
Capsules
aldehyde levels 323, 346, 356(a), 357(a)
container closure system, 323, 350
excipient intrinsic dissolution rates, 330
hard shell
advantages and disadvantages, 321
auger, 335, 340
capacity and sizes, 327
disc, 338
dosator, 340
dosator sequence, 337
encapsulation using semi-automated machine, 336
excipient classes and functions, 322
fill process, 320
fill type
powder, 338
other, 339
formulation design, 320
genelatin capsule composition, 324
hypromellose capsule composition, 325
identification, 326, 339
lipid formulation classification system, 332
optimization of formulation and process, 348–9
optimization process, 348
Capsules (Continued)
  preformulation, 327
    solid state properties, 368
    solution and chemical properties, 368
    process capability index, 340
  pullulan capsule composition, 325
  starch capsule composition, 326
  shell manufacturing process, 320
    dip molding, 320
    injection molding, 325
  soft shell
    advantages and disadvantages, 343
    composition of gelatin soft shell, 345
    composition of starch soft shell, 346
    excipient component classes and functions, 322
    liquid-fill excipients(a)
    manufacture of soft shell, 343
    rotary die process, 345
    stability protocol, 352
  Carbopol, 165–6, 309(a), 394, 396, 409(a),
    463(a), 575, 581(a), 584(a), 617(a)
  Carageenan, 322, 325, 344, 394, 409(a),
    571, 623
  CAS (Cellulose Acetate Succinate), 280
  Cascade Impaction Methods, 127
  CAT, see Committee for Advanced Therapies
  Cathodal delivery, 602
  Cavitation, 386, 576, 608
  CBER, see Center for Biologics Evaluation and Research
  CBRN, see Chemical, Biological, Radiological, or Nuclear
  CCS (Container Closure system), 190, 283,
    350, 401, 443, 530, 577
  CDER, see Center for Drug Evaluation and Research
  CDRH, see Center for Devices and Radiological Health
  Cefazolin Sodium, 88, 93
  Cefepime Hydrochloride, 94
  Cefmetazole Sodium, 94
  Cefotaxime Sodium, 94
  Cefuroxime Sodium, 399
  Cellelectra electroporation system, 607
  Cellulose Acetate Butyrate, 148, 310(a)
  Cellulose Acetate Phthalate, 278, 280,
    306(a), 311(a), 625
  Cellulose Acetate Succinate, 280
  Cellulose methyl cellulose, 628
  Center for Biologics Evaluation and Research, 644–5, 774
  Center for Devices and Radiological Health, 422, 427, 609, 644
  Center for Drug Evaluation and Research, 427, 609, 645
  Center for Food Safety and Applied Nutrition, 644–5
  Center for Tobacco Products, 641, 644–5
  Center for Veterinary Medicine, 644–5, 703
  Centipoise, 74
  Central location measures, 135
    arithmetic mean, 124, 135–7
    geometric mean, 123, 135, 435
    median, 135–6
    mode, 135–6
    percentiles, 135–6
  CEP, see Certificate of Suitability to European Pharmacopoeia
  Cernevit, 389
  Certificate of Analysis (COA), 295, 404,
    660, 873
  Certificate of Suitability (CEP), 817–8
    Revisions & Renewals, 819
  Certificate of Suitability to European Pharmacopoeia (CEP), 817
  CFR, see Code of Federal Regulations
  CFSAN, see Center for Food Safety and Applied Nutrition
  CGMP, see Current Good Manufacturing Practice
  CHADD® (Controlled Heat-Assisted Drug Delivery), 602
  Change control, 683, 685, 831–2, 843,
    845–6, 848–9, 856, 869, 886
  Change control during IQ, 846
  Change in enthalpy, 16–17, 19–20, 22, 67,
    226, 366, 386, 419, 470
  Change in Gibbs free energy, 17, 19–20,
    67, 87, 386–7
  Change in the surface free energy, 59, 362,
    430
Change management, 840, 844, 865–6, 867, 901(a)
Changes and updates to the ASMF, 821
Changes to a DMF, 815
Changes to Approved ANDA
  a major change requiring ‘Prior Approval Supplement’, 758
  a moderate change, 758
  annual report, 759
  changing drug labels, 782
  minor change, 759
Chaotic Rheograms, 78
CHAP, see community health accreditation program
Charcoal
  activated, 67, 602
Charge ratio, see Vectors
Chelating agents, 85, 475, 567, 583(a), 616(a)
Chemical adsorption, 65
Chemical equivalents, 45
Chemical stability, 25, 85, 87, 187, 325, 351, 361, 368, 475–6, 490, 500, 507, 510
Chemical penetration enhancers, 593–4, 596, 606, 612
Chemical vapor deposition, 532
Chemical/Physical adsorption, 65
Chemistry review, 742
Chemistry, manufacturing and control (CMC) information, 737–9
Chemometrics, 22
Children’s Motrin, 76
Chitosan, 68, 163, 165–6, 309(a), 441, 463(a), 574, 582(a)
Chloramphenicol, 704, 780
Chloraseptic®, 164
Chlorpheniramine Maleate, 162, 765
CHMP, see Committee for Medical Products for Human Use
Chronorelease, 620, 633
Chronotherapy, 633
Chymotrypsin, 168
Clausius-Clapeyron equation, 432
Clean Area, 690
Clean/Contained area, 690
Cleaning validation, 223, 830, 854–5
Climatic zone, 890
Clindamycin Phosphate, 95
Clinical equivalents, 45
Clinical hold decision, 743
Clinical phase 4 studies: Post-marketing surveillance & risk assessment, 792
Clinical protocol and investigator information, 737
Clinical studies of MOAs related to efficacy (Phase 2a—also called proof of concept), 741
Clinical studies of pharmacokinetics or imaging with radiolabeled drug, 740
Clinical trials to study pharmacologically relevant doses, 740
Clonazepam, 95
Clonidine patch, 590, 598, 600
Cloud point or cloud temperature, 388
CMC, see chemistry, manufacturing, and controls
CMC/microbiology review Question-based review for CMC evaluations of ANDAs, 756
CMP, 68
COA, see Certificate of Analysis
Coagulation, 361, 363
Coalescence, 60–61, 279, 282, 361, 378–9, 385, 495
Coarse dispersions, 62, 359, 364, 499
Coarse suspension, 360, 364–5, 368, 372, 399
Coatings, 277, 283, 326, 445, 619, 621, 625–6, 631
COC, 304, 547
Code of Federal Regulations, 46, 50, 185, 221, 443, 532, 534, 577, 639, 651–2, 749, 760, 763, 774, 789, 805, 810, 830, 868, 918
Coefficient of determination (R²), 124, 251
Coefficient of variation, 136–7
Colchicine, 705
Cold junction, 516
Collaborative implementation Framework, 943
Collapse temperature of common excipients, 504, 506–7, 515, 558(a)
Colloid mill, 372, 374, 376
Colloid dispersions, 359, 369, 499
dendrimers, 129, 359, 365, 375–6, 479, 574
Colloid dispersions (Continued) vectors, 359, 365, 374–5
Colony forming units (CFU), 404, 527
Combination products, 159–160, 338, 644, 646
Commercial manufacturing, 181, 188, 516, 850, 851, 864, 866, 867, 869
Commercial manufacturing process, 516, 850, 851, 869
Commercial-of-the-shelf (COTS), 884
Comminution, 251, 372
Commissioning, 829–30, 832, 834–7, 839–40, 842, 844, 849, 856
Commissioning plan, 832
commissioning plan close-out, 837
documentation Requirements, 836
equipment commissioning, 837
facility commissioning, 835–6
inspection (site inspection/site acceptance test) (SAT), 837
principles/elements of commissioning, 835
utilities commissioning, 837
Commissioning & qualification
change control, 683–5, 831–2, 843, 845–6, 848–9, 856, 869, 886
cleaning validation, 223, 830, 854–5
commissioning, 829–30, 832, 834–7, 839–40, 842, 844, 849, 856
crcomputer systems validation, 856
preliminary C & Q activities, 832
process validation (PV), 181, 223, 320, 679, 811, 820, 830–831, 835–6, 838, 840–841, 848–9, 850, 852–3, 864, 873
qualification & validation, 518, 838, 840–841
qualification protocols, 839, 842, 843, 856
regulatory requirements, 531, 649, 651, 735, 750, 791, 829, 835, 837, 839
revalidation, 679, 832, 856, 857, 889
Commissioning and qualification (C & Q), 829, 832, 834, 849, 856
Commissioning plan, 832, 836–7, 842
Commissioning plan close-out, 837
Commissioning vs. qualification, 839
Committee for advanced therapies (CAT), 648
Committee for medical products for human use (CHMP), 648
Committee for medical products for veterinary use (CVMP), 648
Committee for proprietary medicinal products (CPMP), 820, 924
Committee on herbal medicinal product (HMPC), 648
Common EMEA/FDA Application for orphan medicinal product designation, 784
Common ion effect, 40, 42
Common technical document (CTD), 756–7, 813
Community health accreditation program (CHAP), 699
Comparing two variances, 146
Complaint files [Sec. 211.198], 675
Complete response (CR), 815
Complex modulus, 79
Complexation, 52, 60, 479
Compliance
patient, 25, 129, 159, 190, 210(a), 289, 447, 499, 588, 613, 621
Component selection and storage, 710
Component, drug product container, closure, and labeling records [Sec. 211.184], 671
Compounded Preparations beyond-use-dating of, 707, 717, 719
stability criteria, 717
Compounder, 708, 710–716, 718
Compounding, 25, 31, 68, 662, 697–720, 722(a), 724(a), 725–6(a), 796
Compounding for a prescriber’s office use, 716
Compounding guidelines, 698
Compounding herbal products, 717
Compounding nonprescription drugs, 717
Compounding of drugs for use in animals—[Sec. 608.400], 699, 702
Compounding pharmacists, 705, 720
Compounding record, 706, 714, 726(a)
Compounding veterinary products, 716
Compression mill, 248
closures (Continued)  
polypropylene (PP), 172, 213(a), 284–6, 810  
poly(vinyl chloride) (PVC), 284, 288–9, 290, 291  
poly(vinylidene chloride) (PVdC, saran), 284, 286  
polyamide (PA, nylon), 284, 286  
containment  
primary containment, 690  
secondary containment, 690  
Content uniformity, 47, 119–21, 227, 238–9, 244, 246, 255–6, 258, 260–261, 265, 274, 276, 293–6 332, 334, 339–41, 351–2, 450–451, 455  
Contents of annual report notification, 791  
Continual improvement of the PQS, 865  
Continuous process verification, 851  
Continuous quality improvement (CQI), 714–5  
Continuous ultrasound, 607  
Continuous variables, 135  
Contour plot, 348, 350, 399  
Controlled heat-assisted drug delivery, 602  
Control number, 661, 664, 675–6, 713  
batch number, 676, 714  
lot number, 659, 661, 671, 674–6, 714  
Control of components and drug product containers and closures, 710  
Component selection and Storage  
Packaging containers and closures, 711  
Control of microbiological contamination (Sec. 211.113), 663  
Controlled area, 691  
Cord length distribution (CLD), 249, 436  
Corrective action and preventative action (CAPA), 865–7, 867, 869, 874, 900(a)  
Cosolvent solubilization, 476  
Cosolvent stabilization, 476  
COTS, see Commercial-of-the-shelf  
Council of Europe, see EC  
Counterions, 167, 364, 371, 604  
Coarse and colloidal solid dispersions, 496  
Cpk, 341  
CPMP, see Committee for Proprietary Medicinal products  
CPSC, see Consumer Product Safety Commission (United States)  
CQI, see Continuous quality improvement  
CR, see Complete response  
Creaming, 60–61, 366, 370, 377–8, 402, 404, 430, 475, 537, 567, 718  
Creams, 73, 80, 207–8(a), 392–5, 401, 404, 526, 596, 701, 718  
Creep curve  
retardation time, 78–9  
Criminal prosecution, 686–7, 799  
Critical micelle concentration (CMC), 387–8  
Critical moisture content, 267, 287–8  
Critical path initiative, 939, 944  
Critical process parameter, 190, 279, 401, 432, 436, 503, 513, 528, 839, 852  
Croscarmellose Sodium, 232, 234, 236, 312(a), 331, 356(a)  
Cross contamination, 218, 664, 670, 679, 706, 709, 833, 854  
Cross model  
zero-shear rate viscosity, 79  
Cryogenic technology  
spray-freezing into liquid, 125, 131  
Cryoprotectant  
sucrose, 127  
Crystalline matrix, 507–9  
Crystallization, 18–9, 27, 119, 125–6, 131, 246, 260, 267, 273, 363, 397–9, 436, 498, 504–5, 508, 514, 527, 718  
CTD, see Common technical document  
CTP, see Center for Tobacco Products  
Cup viscometer, 77  
Current Good Manufacturing Practice  
subpart A—General Provisions Scope, 653  
subpart B—Organization and Personnel, 654  
subpart C—Buildings and Facilities, 655  
subpart D—Equipment, 657  
subpart E—Control of Components and Drug Product Containers and Closures, 658  
subpart F—Production and Process Controls, 661
subpart G–Packaging and Labeling Control, 663
subpart H–Holding and Distribution, 667
subpart I–Laboratory Controls, 667
subpart J–Records and Reports, 670
subpart K–Returned and Salvaged Drug Products, 676
Current trends in qualification, 839
Custom statistical design excipient compatibility, 236
CVMP, see Committee for Medical Products for Veterinary Use
Cyclic olefin copolymers, 533
Cyclic olefin polymer, 533
Cyclodextrin, 17, 53, 60, 357(a), 441–2, 463(a), 479, 480, 574, 582(a)
Dalton’s Law of Partial Pressure, 15
Data evaluation and extrapolation, 892
Data submitted by a drug sponsor, 761
DBP (Dibutyl Phthalate), 311(a)
DBS (Dibutyl Sebacate), 311(a)
DCS, see Distributed Control System
DDMAC, see Division of Drug Marketing, Advertising, and Communications
DEA, see United States Drug Enforcement Agency (United States)
Dealkalinization, 532
Decarboxylation, 85
Decimal decay time (D_{10}), 522
DEGMEE, see Diethylene glycol monoethyl ether
Degradation rate constant, 9, 87–8, 112, 477, 492
Degradation reaction
  first-order, 7, 10, 87–9, 287
  zero-order, 10, 88–9, 892
Degree of flocculation, 364–5, 371
Dehydration, 85, 226, 266, 470–471, 490, 510–511
Delayed and extended release, 619, 628
Dendrimers, 129, 359, 365, 375–6, 479, 574
Density of an ideal gas, 15
DEP (Diethyl Phthalate), 311(a)
Department of Agriculture, 639, 644–5
Department of Education, 639
Department of Education Organization Act, 639
Department of Health and Human Services (HHS), 639
Department of Health, Education and Welfare (United States) (HEW), 639
Department of Transportation (DOT), 488
Department of Veterans Affairs, 731
Deponit, 599
Depyrogenation oven, 525
Descriptive statistics, 135, 137
Design and construction features [Sec. 211.42], 655
Design and content considerations of the PQS, 865
Design Consideration, 219, 833
Design of experiment
  full factorial design, 148–9, 151
Design qualification (DQ), 841, 844, 883–4
Design space, 183, 220, 242, 348, 401, 437, 513, 515, 812, 840
Designation of drugs for rare disease or conditions
  (Sec. 526[21 USC §360bb](a)(1), (b), (c), (d)), 779
Desonide, 89, 95
Detection limit, 333, 888, 905(a)
Determination of volume of injection, 536
Developability, 182, 183–7, 215, 225, 417, 421, 474
Developability classification system, 186
Development safety update report (DSUR), 926
Device-assisted ocular penetration
  electroporation, 975
  iontophoresis, 975
  microneedles, 975
  ultrasound, 975
DeVilbiss, 424
Dew point, 268, 270–272, 282
Dew point temperature, 268
Dexamethasone Sodium Phosphate, 95, 568
Dextran, 68, 397, 464(a), 510–511
Dextrose equivalent, 236
DG Enterprise, see Directorate General for Enterprise of the European Commission
Diameter (d), 120, 123
Diameter of the capillary wall, 259
Dibutyl phthalate, 280, 311(a)
Dibutyl Sebacate, 280, 311(a), 326
Dicalcium Phosphate Dihydrate, 330
Diclofenac Sodium, 596, 597
Dielectric constant of the material, 272
Dielectric of the double layer, 364
Dielectric permissivity of free space, 272
Dietary supplements (DS), 164, 641, 645, 795, 878–9
Dietary Supplement (DS) Health and Education Act, 641
Diethyl Phthalate, 280, 311(a)
Diethylene Glycol, 357(a), 618(a), 705
Diethylene Glycol Monoethyl Ether (DEGMEE), 357(a), 618(a), 705
Diethylstilbestrol, 704, 723(a)
DiFFCORE™, 629
Differential equations, 10
Differential scanning calorimeter (DSC), 267, 506, 882
Differential scanning calorimetry, 19, 40, 43, 167, 226, 336, 470, 506, 509, 882
Differentiation, 10, 11, 587
Diffusion coefficient, 11, 39, 40, 61, 569, 593, 601, 608, 622
Diffusional lag time, 593
Digoxin, 53
Dilatant flow, 76, 77
Diluents and direct compression binders, 229, 307(a)
Diluted Hydrochloric Acid, U.S.P, 29
Dimethyl sulfoxide (DMSO), 595
Dimyristoylphosphatidylcholine (DMPC), 390
Dimyristoylphosphatidylethanolamine (DMPE), 390
Dimyristoylphosphatidylglycerol (DMPG), 390
Diode-Array UV Spectrophotometry, 173
Dipalmitoylphosphatidylcholine (DPPC), 387, 390, 436
Dipalmitoylphosphatidylethanolamine (DPPE), 390
Dipalmitoylphosphatidylglycerol (DPPG), 390
Dipalmitoylphosphatidylserine (DPPS), 390
Direct filling, 327, 335, 338
Directorate General for Enterprise of the European Commission (DG) Enterprise, 651
Disc filling, 338
Discard by date, 718
Disintegrants, 39, 219, 229, 230, 232, 233, 235, 236, 239, 243, 282, 287, 312(a), 330
Disintegration time, 47, 138, 151, 159, 171, 295, 351, 662
Dispersed system product design advantages and disadvantages of oral liquid coarse dispersions, 361
advantages and disadvantages of microemulsion, 393
aggregation number, 387
amphiphile, 386–7, 389
amphiphilic associations, 387
association colloidal, 386
dispensions
hydrophobic effect, 386–7
microemulsions, 61, 319, 331, 344, 359, 361, 367, 377, 392, 393, 405, 478, 565, 600
advantages and disadvantages of microemulsions, 393
micelles, 38, 129, 228, 332, 359, 367, 376, 387–90, 392, 474, 477, 479, 487, 574
niosomes, 359, 367, 389, 574, 600
Bee high pressure homogenizer, 386
bicontinuous, 392
cloud point, 388
cloud temperature, 388
coarse suspensions
process analytical technology, 399
scale-up, 372, 399
taste score, 400
colloidal solid-liquid medium, 374
dispersions
dendrimers, 129, 359, 365, 375–6, 479, 574
vectors, 359, 365, 374–5
composite required HLB, 383
colloid mill, 372, 374, 376
controlled flocculation, 371
coarse emulsions, 361, 367, 377
coarse suspensions, 360, 365, 369, 372, 399
critical micelle concentration for select surfactants, 388
degree of flocculation, 364–5, 371
dispersed system classification, 360
DLVO theory of attractive and repulsive forces, 363
effective HLB, 379
excipients
buffers, 411(a)
emulsifying agents, 411(a)
flocculating agents, 411(a)
phospholipids, 391
structure modifying agents, 371, 409(a)
suspending agents, 368, 475
sweetening agents, 410(a)
viscosity enhancing agents, 365, 441, 565
excipient classes and functions for liquid suspensions and solid colloid dispersions, 369
excipient classes and functions for macroemulsions and association colloids, 370
high shear mixer, 375
hydrophile-lipophile balance (HLB), 161, 332, 367, 379, 388
Ishikawa diagram, 402, 403
kelvin equation, 430
liquid coarse disperse systems, 360, 361
macroemulsions, 360–361, 370, 377, 384, 404–5
scale-up, 385
macromixing, 372–3
micromixing, 386
micronization, 372–3
mixer impellers, 374
multiple emulsions, 384, 385
oil-in-water emulsion, 126, 208(a), 368, 379, 415, 478, 494
Ostwald-Freundlich equation, 362
primary emulsion, 384–5, 409(a)
pumping, 80, 211(a), 372–3, 492
phase-inversion temperature, 378
phase volume, 378–9, 380, 382, 478, 574
preformulation
solid state properties, 226
solution and chemical properties, 421
Power number, 373
required HLB, 367, 379, 380–383, 403, 413–4(a)
reverse micelles, 388
Reynolds number, 81, 189, 373
risk management, 292–3, 350, 402, 446–7, 535, 677–8, 863–7, 867, 868–9, 874, 926
fishbone diagram, 402
Ishikawa diagram, 402–3
secondary emulsion, 385
sedimentation volume, 364–5, 371–2
semi-solid dispersions
creams, 395
gels, 394
ointments, 395
pastes, 395
scale-up, 396
solid dispersions
hot-melt, 396
scale-up, 401
spray-dried, 397, 401
suppository, 397
stability protocol, 231, 234–5, 237, 296–7, 253, 405–6, 455–6, 537–8, 772(a), 890–891
Stokes law, 81, 361, 370–371, 379, 398, 429
suppositories, 62, 158, 205(a), 208(a), 209(a), 360, 397–9, 405, 718
surface free energy, 59, 362, 430
surfactant parameter, 389–90
suspensions
scale-up, 399
water-in-oil emulsion, 208(a), 378–9
zeta potential, 62, 130, 364
Dissolution, 25

dissolution at time (Ruator

dissolution at time t for the test product (Tuator

Dissolution rates of capsule excipients, 357(a)
Distearoylphosphatidylcholine (DSPC), 390
Distearoylphosphotidylglycerol (DSPG), 495–6
Distributed control system (DCS), 856
Distribution procedures [Sec. 211.150], 667
Distribution records [Sec. 211.196], 675
Division of Bioequivalence, 757
Division of Drug Marketing Advertising and Communications (DDMAC), 795
DLVO theory, 363
DMF, see Drug Master File
DMF Formats and Review Process
DMF (CTD/eCTD) Formats, 813
Common Technical Document (CTD) for DMFs, 813
electronic filing of DMFs and CTD, 814
DMF formats and review process, 814
Dobutamine Hydrochloride, 96
Documentation requirements, 745, 836, 857
Docusate Sodium, 52, 315(a)
Dosator filling, 335
Dosator sequence, 337
Dosage form nomenclature
FDA nomenclature, 619, 636(a)
USP nomenclature, 207(a)
Disc encapsulation, 338
Doxazosin Mesylate, 162
Doxorubicin, 66, 67, 129, 494, 496
DQ, see Design qualification
Droperidol, 96
Drug approval activities, 789
Drug blood profile, 4, 6, 7, 47–8, 592, 620
Drug clearance (Cl), 439, 592
Drug compounding controls, 711
Drug compounding facilities, 708
Drug concentration in the formulation (Cf), 590, 592
Drug concentration in the stratum corneum (Csc), 592
Drug development process, 181, 782, 727
Drug diffusion coefficient, 608
Drug Enforcement Administration, 644
Drug flux, 591–2, 603
Drug intermediates, substances, and material used in their preparation, 809
Drug master file, see DMF
DMF formats and review process, 813
holder obligations, 815
submissions to Drug Master Files, 807
type of Master Files, 808
Drug name confusion, 797
Drug Price Competition and Patent Term Restoration Act, 640, 754
Drug product
data evaluation and extrapolation, 892
photostability testing, 890, 891, 907(a)
selection of batches, 891
specification, 891
stability commitments, 892
storage statements/labeling, 893
Drug product characterization
dry powder inhaler, 128, 191, 324, 416–7, 420, 422, 433–5, 450, 454
pressurized metered dose inhaler, 416–7, 422, 432
Drug product containers and closures [Sec. 211.94], 660
Drug product inspection [Sec. 211.134], 666
Drug product salvaging [Sec. 211.208], 676
Drug release studies
first-order, 124
Higuchi’s model, 124
Kopcha’s model, 124
Korsmeyer-Peppas’ model, 124
zero-order, 124
Drug research and children, 780
Drug shortages, 797
Drug’s apparent diffusivity, 591
Drug’s diffusional coefficient, 622
Drug’s skin permeability coefficient, 591
Drug’s stratum corneum-formulation partition coefficient, 591
Dry bulb temperatures, 268
Dry granulation, 221–2, 235, 246, 258, 262–3, 275, 312(a), 626
Dry Heat Sterilization, 524, 526
Dry Powder Inhalers, 128, 191, 324, 416–7, 420, 433, 435, 450, 454
Drying surface area, 269
INDEX 961

DS, see Dietary Supplement
DSC, see Differential scanning calorimetry
DSUR, see Development Safety Update Report
Dulcolax Milk of Magnesia, 76
Dupel iontophoretic system, 606
Duragesic, 595, 600, 782
DuraSite suspension system, 572
Durham-Humphrey Amendment, 640
Dwell time, 264–5, 274, 275, 277, 339
Dynamic light scattering, 121, 130
laser light diffraction, 120
Dynamic rigidity, 79
Dynamic vapor sorption methods, 20
Dynamic viscosity, 79, 80
EC, see European Commission
eCTD, see Electronic Common Technical Document
EDMF, see European Drug Master File
EDQM, see European Directorate for the Quality of Medicines
EDR, see Enhanced design review
E-Trans iontophoretic system, 604
Effect size, 139
Effective concentration, 165, 185, 621
Effective dose, 185
Effective HLB, 379
Effective pore size, 161
Effectiveness check levels, 691
Effectiveness checks, 691
Effects of freeze concentration, 507
EFPIA, see European Federation of Pharmaceutical Industries and Associations
EFTA, see European Free Trade Association
Einstein equation, 61
EIS, see Environmental impact Statement
Ejection time, 275
Elastic (storage) modulus, 79
Elastic deformation, 80, 247, 264, 275, 326
Elastic niosomes, 600
Elastic properties, 73, 78–80, 351, 396
Elastomer, 445, 450, 469, 530, 531–5
Elastomeric closures, 530, 533
Electric double layer, 121, 125, 127, 129–130, 171, 509
Elimination rate constant, 8
Elixirs, 75, 86, 208(a), 717
EMA Responsibilities/Committees, 647
Emergency use IND, 735
Emisphere’s eligen®, 168
Emulsifying agents, 28, 199(a), 367, 370, 411, 495
Emulsion, 60, 227(a), 404, 478, 494, 718
emulsifying agents, 28, 367, 370, 411(a), 495
Emulsion inversion point (EIP), 379–80
Emulsion solubilization, 478
Emulsion stabilization, 477–8
Encapsulation (semi-automated machine), 336
Encapsulation efficiency, 125
Endothermic, 20, 22, 31, 67, 515
Endotoxins, 68, 420, 467, 486, 524, 536–7
removal, 524, 526
forms of, 15, 17
Enhanced design review (EDR), 844
Enrobed, 630–631
Enteric coatings, 326, 619
Enthalpy, 16, 17, 19, 20, 22, 67, 226, 366, 386, 419, 470
Entropy, 17, 18, 19, 22, 67, 386, 392
Entropy change, 17, 18, 19, 22, 67, 386, 392
Environmental assessment, 812
Environmental equivalency, 281
Environmental impact statement (EIS), 812
EP, see European Pharmacopeia
EPA, see Environmental Protection Agency (United States)
EPDM (ethylene propylenediene monomer), 533
Ephedrine Sulfate, 96
Epidemiology, 792, 794
Epimerization, 85
EQ, see Equipment qualification
Equipment cleaning and maintenance [Sec. 211.67], 657
Equipment cleaning and use log [Sec. 211.182], 671
Equipment commissioning
post delivery/on site commissioning activities, 837
pre-delivery inspection (PDI) and factory acceptance test (FAT), 837
Equipment construction [Sec. 211.65], 657
Equipment design, size, and location [Sec. 211.63], 657
Equipment identification [Sec. 211.105], 662
Equipment maintenance and performance checks, 886
Equipment qualification (EQ), 830, 838
Equivalent diameter, 120
Equivalent spherical diameter, 120
Equivalent sterilization time (F₀), 523–4
Equivalent weight, 29–31
Estradiol patch, 590, 598
Ethacrynic Acid, 96
Ethacrinic Acid, 96
Ethanol, 21, 35–6, 58, 258, 273, 347, 358(a), 392, 421, 431–2, 442–3, 463–6(a), 476, 479, 480, 488, 500, 548–9(a), 582(a), 596–8, 601, 615–6(a), 618(a), 903(a)
Ethosomes, 600–601
Ethylene glycol dimethacrylate-N-methacryloyl-l-histidine, 67
Ethyleneiminietetaacetic Acid, 67, 484
EU, see European Union
EU Dossiers, 805
EU Good Manufacturing Practice, 677
chapter 1 Quality Management, 677
chapter 2 Personnel, 678
chapter 3 Premises and Equipment, 679
chapter 4 Documentation, 679
chapter 5 Production, 679
chapter 6 Quality Control, 680
chapter 7 Contract Manufacturing and Analysis, 680
chapter 8 Complaints and Product Recall, 680
chapter 9 Self Inspections, 680
Eudragit E100, 163
Eudragit NE 30 D, 162
Eudragit RL, 124, 162, 278, 625
Eudragit RS, 124
EUDRAGIT® polymers, 124
Eudramode™, 162
European Commission (EC), 323, 646–7, 677, 784
European Directorate for the Quality of Medicines, 1870, 2040 (EDQM), 818
European Drug Master File (EDMF), 817, 820
European Drug Master File (EDMF)/Active Substance Master File changes and updates to the ASMF, 817
European Federation of Pharmaceutical Industries and Associations (EFPIA), 650
European Free Trade Association (EFTA), 646, 650
European Marketing Authorization Dossiers Certificate of Suitability (CEP), 817
European Drug Master File (EDMF)/Active Substance Master File, 820
full details of manufacture, 821
other evidence of suitability of the pharmacopoeial monograph, 822
EDQM inspection program, 819
European Medicines Evaluation Agency (EMEA), 422, 424, 646, 778, 784, 818
European Pharmacopeia (E.P.), 220, 241, 481, 647, 817–8, 822, 877, 879–80
European Union (EU), 287, 297, 353, 456, 646, 652, 778, 818, 822, 879, 881, 911
Eutectic collapse temperature, 504
Eutectic composition, 504–5
Eutectic freezing, 504
Eutectic mixture, 395, 504, 505, 508, 601
Eutectic system, 333
Eutectic temperature, 504–7, 558(a)
Evaluation activities, 715, 870, 874, 903(a)
Evamist, 597
Evaporation rate constant, 438
EWG, see Expert working group
Excipient(s)
   aldehyde levels, 323, 346, 356(a), 357(a)
   dielectric values, 273
   loss tangent values, 79, 272, 273
   guidelines; functions of excluded solute hypothesis, 510
Exothermic, 20, 22, 31, 276, 504, 602
Expanded access to new therapies
   parallel track (1992), 777
   treatment IND (1987/revised 2009), 776
Expanded or reducing formulas, 12
Expedited review and approval of new therapies, 775, 776
Expert Working Group (EWG), 650, 881
Expiration date, 666, 668–70, 675, 718–9, 755, 770, 893
Expiration dating [Sec. 211.137], 666
Expiry/expiration date, 896
Exploratory (or phase 0) IND studies, 735
Exponential function, 3
Export application, 805
Extractables
   2,4,6-tribromopheno, 173
Extraction
   multiple extraction procedure, 86
Extragranular, 241, 242
Extralabel drug use in animals, 704
Extralabel use, 704
Extrusion, 52, 120, 221, 222, 224–5, 243, 258, 271, 330, 334, 396–7, 574–5, 626, 628
Exubera, 167, 434
Eye anatomy, 561, 562
Facility commissioning, 835–6
Factors affecting stability, 717
Factory acceptance test (FAT), 836–7, 842
Fair Packaging and Labeling Act, 640
Falling-sphere viscometer, 77
Family Smoking Prevention and Tobacco Control Act, 641, 645
Farday’s law, 603, 605
Fast track, 774–6
Fast track drug development programs (1997), 775
Fasted simulated intestinal fluid, 228
Fasting blood glucose, 305
FAT, see Factory acceptance test
FDA, see Food and Drug Administration
   approach to inspect QC laboratories, 875
   drug dosage form nomenclature, 197(a)
   Form 483, 686, 793, 877
   inspection and regulatory actions
   inspection deficiency observations, see (Form 483), 652
   news release, 701
   package type nomenclature, 209(a)
   regulatory actions taken by the FDA, 685
   responsibilities/centers, 642
   route of administration nomenclature, 184
FDAAA, see Food and Drug Administration Amendments Act
FDAMA, see Food and Drug Administration Modernization Act
FDCA, see Federal Food, Drug, and Cosmetic Act
FDS, see Functional design specification
Fed simulated intestinal fluid, 228
Federal Food, Drug, and Cosmetic Act (FDCA) (FD&C Act), 685, 736, 774, 829
Federal records center, 817
Federal security agency, 639
Federal Trade Commission (FTC), 643
Fentanyl patch, 600
Fentanyl nasal spray, 442
Fiber, 199(a), 205(a), 564, 587, 658
Fick’s law, 39, 590
Field office preapproval inspection review, 747
Field-flow fractionation methods, 130
Film Coating, 159, 216–8, 218, 277–80, 280, 281–2, 283, 329, 362(a)
Film-coat excipient classes, 280
Film-coat excipient functions, 279, 280, 281, 282, 283, 293–4, 295, 320, 321, 629
Film-coating, 279–82, 283
Filters [Sec. 211.72], 658
Filtration sterilization, 529
Final monograph or final amendment prepared, 763
Final monograph/amendment published in the FR and CFR, 763
Finding of no significant impact (FONSI), 812
Fine particle fraction, 416, 419
Finished product, 670, 678, 708, 725(a), 755, 831, 838, 850, 852, 856, 869, 873, 889, 916
First falling rate period, 267–8
First Law of Thermodynamics, 16, 18
First pass metabolism, 184, 215, 220, 418, 439, 465(a), 567, 601, 608
Fluorescence, 256, 465(a), 567, 685(a), 593, 601, 608
Fluid properties, 73
Fluid-bed, 126, 158–9, 222–3, 260, 266, 269–71, 278–9, 283, 329
Fluid-bed granulation, 158–9, 222, 223, 260, 266, 269–71, 329
Fluid-bed granulator, 269
Flux, 39, 45, 215, 573, 591, 592, 596, 602–3, 605, 610, 633
Focused beam reflectance measurement, 249
FOIA, see Freedom of Information Act
FONSI, see Finding of no significant impact
Food and Drug Administration (FDA) Act, 641
Amendments Act (FDAAA), 789, 798
key milestones, 639
Modernization Act, 641, 781, 789, 791
Food and Drug Law History, 639
Food and Drugs Act, 640, 878
Food Chemicals Codex, 220, 710
Forced degradation, 86, 187, 887, 905(a), 906(a)
Forced degradation conditions guidelines: solids, 906(a)
Forced degradation parameters for drug substance (API), 905(a)
Foreign government agencies, 639
Formulation and process optimization, 243, 348, 349
Formulation design, 222, 360, 416, 468, 565, 590
Formulation optimization, 188, 242
Formulation record, 714, 724(a), 726(a)
Fourier Transform Infrared Spectrophotometry, 173
Fractional Factorial Design, 152, 154
Fracture tensile strength, 265
Free energy, 17, 19, 20, 50, 60, 67, 87, 362, 369, 371, 386, 387, 430
Freedom of Information Act (FOIA), 790, 809
Freeze concentrate, 505, 507–8, 558(a)
Freeze drying cycle, 502
Freeze-thaw cycle, 405, 456, 538, 601
Freeze-dried cake, 501
Freezing of a crystallizing system, 505
Freezing of a noncrystallizing system, 506
Freezing and metastable solid phases, 508
Freezing point of concentrated solution (\(f_{p_{c}}\)), 505
Frequency factor, 87–9
Frequency in Hz, 272
Freundlich adsorption isotherm, 66
Freundlich and Langmuir isotherms, 67
Frictional coefficient, 593
Froude equation, 493
Froude number, 189, 257, 262, 493
FS, see Functional specifications
FTC, see Federal Trade Commission
FTIH, see First time in human
Full details of manufacture, 817, 820–821
Functional adjuvants, 217
Functional class screening, 231–2
Functional design specification (FDS), 843
Functional specification (FS), 841, 843–4, 846
Functional design specification (FDS), 843
Fungi colony forming unit (cfu.), 404
Fungizone, 389
Furosemide, 97
Gabapentin, 753, 783
Gamma radiation sterilization, 526
Gang-printed labeling, 663
Gas constant, 11, 15, 19, 21–2, 61, 67, 88, 363, 432, 482
Gas law, 12, 15, 282
Gas law equation for an ideal gas, 14
Gastrointestinal permeation Enhancement technology, 164
Gastrointestinal tract, 102, 131, 163, 215, 345, 393, 418, 588, 632
Gastroretentive devices, 631
Gastroretentive systems, 161
Gaviscon®, 161
GCC, see Government Coordinating Council
GCPs, see Good Compounding Practices
Gelatin, 52–3, 62, 160, 308(a), 319–20, 322, 323, 324, 326–8, 331–2, 339, 343, 344, 345, 346–8, 351–2, 359, 384, 394, 398, 413(a), 433, 492, 500–511, 550(a), 556(a), 558(a), 617(a), 629, 636(a), 723(a)
Gelatin hard-shell capsule, 323, 324
Gelatin hard-shell capsule formulation, 324
Gel-forming ophthalmic solutions, 571
Gels, 80, 202(a), 207(a), 319, 323, 360, 365, 392, 394, 401, 404, 441, 571, 596, 718
Gene delivery, 170
Gene endpoint, 932
Gene mutation, 921
Generally Recognized as Safe (GRAS), 221, 325, 499, 534, 594, 711, 738, 762, 764, 811
Generic drug labeling, 754, 757
Generic drug review process
accept/refuse to file letter issued, 756
ANDA/AADA approved, 758
applicant, 755
bioequivalence review, 756
changes to approved ANDA, 758
CMC/microbiology review, 756
labeling review, 757
preapproval/request for plant inspection, 757
Generic medicinal product, 769
Generics, 645
Genotoxicity, 728, 911–2, 919–23
Genotoxicity testing, 920
recommendations for in vitro tests, 921
recommendations for in vivo tests, 922
the standard test battery for genotoxicity, 920
Geometric mean, 123, 135, 436
Geometric mean diameter, 435
Geometric standard deviation, 123, 452
GHTF, see Global Harmonization Task Force
Gibbs free energy, 19, 20, 386
Glass, 65, 69, 172, 210(a), 211(a), 213(a), 285–6, 292, 401, 471, 484, 489–91, 498, 502–3, 522, 524, 525, 530–33, 609, 711, 883
types, 65, 285, 531
Glass collapse temperature, 504–6, 558(a)
Glass container, 211(a), 213(a), 285–6, 292, 489, 531
Glass lamellae, 531
Glass transition temperature, 89, 112, 246, 279, 397, 505–6, 558(a), 623
Gliadel wafer degrading implant, 623
Glidants and flow aids, 229, 230, 315(a)
Glipizide, 162
Global cooperation group (GCG), 650
Global harmonization, 649, 652
Global harmonization task force (GHTF), 651
Glumetza™, 161, 632
Glycerin
humectant, 27, 367, 394, 441, 595
preservative, 27, 552–3(a)
solvent, 27, 208(a), 364, 432, 480, 548(a), 584(a), 595, 599, 605, 618(a)
wetting agent, 27
Glyceryl Monostearate, 162, 281, 311(a), 313(a), 357(a), 411(a)
Glycopyrrolate, 97
Glycosylation, 69, 167
degree of, 69
Glytrin sublingual spray, 443
GMP, see Good Manufacturing Practice
Good Compounding Practices (GCP), 698–9, 705
compounding for a prescriber’s office use, 716
compounding herbal products, 717
compounding nonprescription drugs, 717
compounding veterinary products, 702, 716
control of components and drug product containers and closures, 710
drug compounding controls, 711
drug compounding equipment, 709
drug compounding facilities, 708
labeling controls, 713
organization and personnel, 706
quality control and continuous quality improvement program, 714–5
records and reports, 714
Good Laboratory Practice (GLP) compliance, 741, 887, 918
Good Manufacturing Practices, 146, 320, 443, 480, 641, 671, 755
Gouy-Chapman layer, 364
Government Coordinating Council, 796
Gral high shear granulator, 260
Grants and contracts for development of drugs for rare diseases and conditions (Sec. 527[21 USC §36022(a)]), 779
Granulation-extrusion-spheronization process, 626
Granule porosity, 259
GRAS, see Generally Recognized as Safe
Gravitational constant, 373
Ground state viscosity, 78
Growth hormone, 168, 436, 490, 492, 500–501, 535, 612, 919
Habitrol, 600
Hammer mills, 125, 243, 246, 250
Hard-shell capsule component classes and functions, 322
Hard-shell capsule sizes and capacities, 327
Hard-shell capsules, 319–20, 321, 323–9, 331–4, 338–9, 343, 346, 397
Hard-shell starch capsule composition, 326
Hatch and Choate equations, 123
Hatch-Waxman Act, 640, 754
Haze, 534
Health and Human Services (HHS), 639, 641, 779
Health Canada, 650–651, 829, 832, 841–2, 852, 854
Heat capacity, 17, 20, 22, 89
Heat of vaporization, 269, 282, 430, 432
Heat transfer coefficient, 269
HED, see Human equivalent dose
Hemolysis, 33, 476, 488, 494
Heparin, 168, 705
Heparin Sodium, 98
Herbal medicinal product, 648
HEW, see Department of Health, Education and Welfare (United States)
HHS, see Department of Health and Human Services
High density polyethylene, 231(a), 284–5, 286, 401, 528, 600, 810
High density polyethylene bottles, 810
High efficiency particulate air (HEPA), 512, 655
High pressure microspray nebulizers, 424
High shear fluid processing technology, 128
Higuchi’s model, 124, 166
HIV, 646, 774, 777, 780, 911
HLB, see Hydrophilic-lipophile balance
HMPC, see Committee on Herbal Medicinal Product
Holder obligations, 815
annual updates/annual reports (ARs), 816
appointment if an agent, 816
changes to a DMF, 815
DMF retiring and closures, 817
listing of persons authorized to refer to a Drug Master File, 815
major reorganization of a DMF, 817
transfer of ownership/agents as holders, 816
Hollow microstructured transdermal system (hMTS), 610
Hooke’s Law, 247
Hot melt excipients, 230, 309(a), 334
Hot-melt, 52, 221, 222, 225, 230, 243, 258, 309(a), 329, 332–4, 351, 360, 396–7, 623, 628–9
Hot-melt capsule formulations, 333
Hot-melt extrusion, 52, 221, 225, 243, 258, 396, 397
Hot-melt solid dispersions, 396
Housekeeping waves, 215–6, 220, 439, 621
HPMCAS, see Hydroxypropylmethylcellulose acetate succinate
HPMCP, see Hydroxypropyl methylcellulose phthalate
Human equivalent dose (HED), 912, 935(a), 936(a)
Human maximum absorbable dose, 168
Human serum albumin, 68, 171, 490, 510, 558(a)
Hydralazine Hydrochloride, 98, 160
Hydroalcoholic solutions, 21, 422
Hydroance™, 164
Hydrocortisone, 34
Hydrocortisone Sodium Succinate, 98
Hydrodynamic diameter, 120
Hydrofluoroalkane (HFA), 421, 429
Hydrogenated soy phosphatidylcholine (HSPC), 479, 495
Hydroydysis, 85, 86, 88, 112, 323, 347, 473, 477, 480, 488, 491, 495, 623, 887, 890, 905(a)
Hydronium ions concentration, 3
Hydrophilic-Lipophile Balance, 161, 332, 367, 379, 388
Hydrophilicity, 36
Hydrophobic, 69, 163, 230, 313(a), 364, 371, 386–7, 389, 433, 475, 500, 532, 565, 567, 573–4
Hydrous lactose, 330
Hydroxyethyl cellulose, 280, 308(a), 409(a), 584(a), 600, 618(a)
Hydroxyprogesterone caprate (Makena), 701
Hydroxypropyl cellulose, 163, 236–7, 280, 308–9(a), 356(a), 409(a), 617(a), 633
Hydroxypropyl methylcellulose, 43, 149, 160–161, 165, 309(a), 319, 410(a), 575, 623, 628
Hydroxypropyl methylcellulose phthalate (HPMCP), 280, 305
Hydroxypropylmethylcellulose acetate succinate (HPMCAS), 305, 408
Hygroscopicity classification system, 306(a), 306, 509
Hydromellose, 236–7, 241, 242, 259, 280–281, 308(a), 310(a), 319, 322, 323–4, 325, 327–9, 333, 347, 356(a), 371, 410(a), 568, 575, 584(a), 628, 630–3
Hydromellose hard-shell capsule, 324–5, 328
Hydromellose hard-shell capsule formulation, 325
Ibuprofen, 339, 753, 781
ICCR, see International Cooperation on Cosmetic Regulations
ICH, see International Conference on Harmonization
Ideal gas law constant, 11, 15, 19, 21–2, 61, 67, 88, 282, 432, 482
IFPMA, see International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland, 650
Immediate (primary) pack, 896
Immediate-release hard-shell capsule, 329
Immobilization mechanism, 511
Immunotoxicity studies, 923
factors to consider in the evaluation of potential immunotoxicity, 924
selection and design of additional immunotoxicity studies, 925
timing of immunotoxicity testing in relation to clinical studies, 926
Impact assessment, 834
Implementation of continuous process improvement, 840
IMS health, 753
Invacare reusable jet nebulizer, 424
In situ screening method, 40
Inactivation factor (N₀/N), 522
Inactivation factor or sterility criteria [Nabla (V)], 522
Inactive ingredient, 411–2(a), 414(a), 420, 465(a), 474, 549(a), 550(a), 552–5(a), 557(a), 571, 597
Inactive ingredients list, 411–2(a), 414(a), 420, 465(a), 474, 549(a), 550(a), 552–5(a), 557(a), 571, 597
Increase formulation viscosity, 568
IND, see Investigational New Drug
IND application review process chemistry review, 742
medical review, 742
pharmacology/toxicology review, 743
safety review, 743
Indirect filling, 335, 338
Indomethacin Sodium Trihydrate, 99
Industrial Hygiene Safety, 243–4
Industrial pharmacy, 157, 183
Inferential statistics, 137
Information request (IR), 815
Inhalation drug delivery system, 415
Inhalation system, 416, 421, 427–8, 447, 455, 609
Initial number of microbes (N₀), 522
Injunction, 640, 687, 701, 704, 794, 799
Innovator drug, 753–4
Ion exchange agents, 567, 583(a), 617(a)
Iontopatch wearable electronic disposable drug delivery system, 606
IONSYS iontophoretic system, 606
In-process control, 159, 294, 320, 662, 678, 838, 852–3
In-process material, 190, 626, 654–5, 662–3, 667, 670, 673, 706–9, 830–831, 869
Inspection, 812–3, 819, 831, 836–8, 842, 850, 857, 864, 866, 869, 870, 875, 878
for cause inspection, 692
Inspection (site inspection/site acceptance test (SAT), 837
Inspection and regulatory actions, 685
regulatory actions taken by the FDA, 685
Inspection of pharmaceutical quality control laboratories, 875
FDA approach to inspecting QC laboratories, 875
Installation qualification (IQ) change control during IQ, 846
IQ Protocol, 845
summary report, 847
Institute for safe medication practices (ISMP), 796
Institutional review boards (IRB), 730
Instrument categories, 882
Insulin human, 65–7, 163, 167–8, 186, 534, 536, 443, 492, 496, 498–9, 600, 610–612, 665, 766, 919
Integration, 10, 432
Integration constant, 432
Interfacial transfer process (k), 627
Interim marketing not permitted (pending subsequent notice), 764
Interim marketing permitted (at risk), 763
Intermediate precision, 888, 905(a)
Intermediate product, 678
Internal energy, 12, 16, 19
International Academy of Compounding Pharmacists, 720
International Conference on Harmonization (ICH), 86, 182, 231, 296, 328, 406, 446, 455, 535, 647, 650, 863, 911
International Cooperation on Cosmetic Regulation (ICCR), 651
International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Products (VICH), 647, 651
International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland (IFPMA), 650
International Federation of Pharmaceutical Manufactures & Associations, 524
International Pharmaceutical Aerosol Consortium on Regulation & Science, 447
International Pharmaceutical Excipients Council, 220
International Society For Pharmaceutical Engineering (ISPE), 834, 840, 842, 844, 856
Interval scale, 135
Intradermal, 53, 195(a), 467, 549–50(a), 552–3(a), 557(a), 610, 612
Intraject needle-free injection system
Intramuscular, 53, 186, 195(a), 394, 467, 499, 535, 549(a), 550(a), 552–4(a), 557(a), 612
Intravenous, 3, 46–7, 49, 52–3, 65, 90, 96, 164, 196(a), 389, 392, 467–8, 472, 477, 494–5, 549–50(a), 552–5(a), 557(a), 606, 697, 723(a)
Intravenous administration, 3, 46, 52–3, 196(a)
Intravitreal injections and implants, 576
Investigational new drug (IND), 700, 727, 732, 734
applicant (Drug sponsor), 736
clinical hold decision, 743
exploratory (or phase 0) IND studies, 735
IND application review process, 742
Investigational new drug application, 700, 736, 738, 774
notify sponsor, 743
sponsor notified of deficiencies, 744
study ongoing, 744
types of INDS, 735
animal pharmacology and toxicology studies, 737, 739
chemistry, manufacturing and control (CMC) information, 738
clinical protocol and investigator information, 737
good laboratory practice (GLP) compliance, 742
Ion transport number, 603, 605
Iontophoretic drug delivery system, 603
IQ, see Installation qualification
IQ protocol, 845–6
IR, see Information request
IRB, see Institutional Review Boards
Irrigating, 25
Ishikawa diagram, 402, 403
ISMP, see Institute for Safe Medication Practices
Isoelectric point, 316(a), 323, 473, 490, 602, 605
Isoniazid, 99
Iso-osmolar, 33
Isosorbide dinitrate, 160
Isothermal, 15, 18, 20, 36, 170
Isothermal stress methods, 170
Isothermal transformation, 15
Isotonic, 33–4, 92, 169, 424, 475, 485, 496, 564, 567, 577
Ivermectin, 162
Japan MHLW Ministerial Ordinances, 680
MHLW Ministerial Ordinance No. 179, 2004, 680
on standards for manufacturing control and quality control of drugs and quasi-drugs, 683
Japan MHLW Ministerial Ordinances on Standards MHLW Ministerial Ordinance No. 136, 2004, 680
on standards for quality assurance for drugs, quasi-drugs, cosmetics and medical devices, 680
Japan Pharmaceutical Manufacturers Association (JPMA), 650
Japanese Pharmacopeia (JP), 232
JCAHO, see Joint Commission on Accreditation of Healthcare Organizations
Jet mill, 125–7, 248, 252, 498
Jet nebulizers, 424–5
INDEX

Joint Commission on Accreditation of Healthcare Organizations (JCAHO), 699
Joint United Nations Programme on HIV (UNAIDS), 780
JP, see Japanese Pharmacopeia
JPMA, see Japan Pharmaceutical Manufacturers Association
Kaletra melt-extrusion, 629
Kefauver-Harris Drug Amendments, 640
Ketamine Hydrochloride, 99, 114
Ketorolac Tromethamine, 99, 115, 171
Key milestones, 639
Kinematic viscosity, 75, 82
centistokes, 75, 82
stokes, 75, 82
Kinetic energy for the drug, 593
Knowledge management, 864, 866–7, 896
Kollidon® CL-F, 39, 309, 312, 617
Kollidon® CL-SF, 39, 309, 312
Kraft temperature, 388
Label claim, 89, 341–2, 348–9, 350, 355, 535, 539
Labeling (product/promotional), 802
Labeling contents, 802
Labeling controls, 713
Labeling issuance [Sec. 211.125], 664
Labeling requirements exceptions, 802
Labeling review, 749, 757
Laboratory animals [Sec. 211.173], 670
Laboratory records [Sec. 211.194], 674
Lacriscert, 575
Langmuir isotherms, 66, 67, 71
Laplace capillary rise equation, 529
Large unilamellar vesicles, 170, 177, 389, 408
Large unilamellar vesicles, 390
Large volume parenterals, 116, 211, 468, 485, 532, 538, 547
Laser ablation, 601, 611
Laws of thermodynamics, 15, 18
Zeroth Law of thermodynamics, 15, 24
Leachables, 172–3, 191, 285, 444, 448–9, 452, 531, 533, 577
polycyclic aromatic hydrocarbons (PAHs); 172
n-nitrosamines, 172
Length of the hydrocarbon chain, 389
Lethal dose, 185, 194
Letter of access, 820, 826
Letter of authorization, see LOA, 805, 807, 811, 814, 816, 820
Levothyroxine Sodium, 99
Lidding construction p, 290
Lidocaine Hydrochloride, 100, 163
LidoSite iontophoretic system, 606
Life threatening diseases, 773
Lifecycle, 836, 896
Light induced fluorescence, 256, 305
Lighting [Sec. 211.44], 655
Linearity, 8, 356, 868, 896, 898, 905
Lip’ral™, 38, 164
Lipid formulation classification system, 332, 356
LipoBridge®, 165
Lipocine Technologies, 38
Lipophilicity, 36, 163, 379, 439, 440, 572, 573
Lipoplex, 375
Liposome solubilization, 479
Liposome stabilization, 479
multilamellar vesicles, 170, 389
small unilamellar vesicles, 170, 389
small unilamellar vesicles, 390
Liquid dosage forms, 25–6, 73, 75, 129, 134, 719
Liquid nitrogen, 125, 244, 528
Liquifilm, 568
Lisinopril, 100
Lisopro, 65
Listerine®, 60, 75, 164
Load monitors, 524, 526
LOAEL (Lowest observed adverse effect level), 932
Logarithmic functions, 8, 14
Long term (real time) testing, 730, 892, 896
Lotions, 392
Lovastatin, 52
Low density polyethylene (LDPE), 424, 444, 462, 57
Lower observed adverse effect level (LOAEL), 932
Lower observed effect level, 244, 305
Largest therapeutic dose, 244, 305
INDEX 971

pressure rise, 516–7
Lyophilization cake, 508
Lyophilization techniques, 158
Lyophilized powder for reconstitution, 501
Lyophilizer, 514
MA, see Marketing authorization, 818, 820–822
Maalox, 76
Macro flux microneedles system, 610
Macromixing, 372, 373
Mad cow disease, 323
Magnesium Sulfate, 100, 556, 715
MAH (Marketing authorization holder), 682, 693
Maillard reaction, 236, 491, 494
Maintenance [Sec. 211.58], 657
Major equipment, 662, 671–3, 859
Major reorganization of a DMF, 817
Major repairs or modifications, 886
Makena, 701
Management responsibilities, 797, 865–7, 870, 898, 908
Manual of policies and procedures (MaPP), 797
Manufacture of soft-shell capsules, 321, 343–7, 351, 520
Manufacturing operations, 268, 870, 872, 902
MaPP, see manual of policies and procedures, 810
Market withdrawal, 692–4
Marketing authorisation application (MAA), 646–7, 677–8, 682, 739, 818–9, 853, 913, 924
Marketing authorization (MA), 646–7, 677–8, 682, 739, 818, 853, 913, 924
Marketing authorization holder (MAH), 682, 693
Marketing pack, 896, 907
Mass, 13, 15, 16, 17, 23, 120, 167, 222, 251, 253, 250, 260, 265, 268, 358, 362, 388, 565
Mass of powder blend, 259
Mass of powder in the mill, 253
Mass spectrometry, 167, 173
Mass transfer coefficient, 268
Master production and control records [Sec. 211.186], 672
Master production document, 860
Material of construction (MOC), 402, 611, 809–810, 826, 860
Materials examination and usage criteria [Sec. 211.122], 663
Mathematical rules, 3, 8
Matrixing, 296, 455, 891, 896
Maximal feasible dose (MFD), 932
Maximum allowable product temperature, 266, 504
Maximum daily exposure of selected solubilizing agents, 480
Maximum freeze concentration, 505
Maximum recommended starting dose (MRSD), 912, 932–3, 935
Maximum tolerance dose (MTD), 932–3
Maxwell unit, 78
MCMs (Medical countermeasures), 943, 945
MDUFMA, see Medical Device User Fee and Modernization Act, 641, 693
Mean surface diameter, 122
Mean surface-volume diameter, 122
Mean volume diameter, 122
Measures for dispersion relative standard deviation, 136–7, 147, 216
standard deviation, 122–3, 136–7, 139, 147, 341
variance, 136–7, 140, 144, 146–7, 255
Measures for kurtosis, 139
Measures for variability, 136
Measures of kurtosis, 137
Measures of skewness, 137
Mechanism of action (MOA), 596, 732, 736, 739, 914, 925, 929
Mechlorethamine Hydrochloride, 101
Medical countermeasures (MCMs), 943
Medical Device Regulation Act, 640
Medical Device User Fee and Modernization Act (MDUFMA), 641, 693
Medication errors, 796
bar code label rule, 796
drug name confusion, 797
MedWatch, 793, 795, 804
MedWatch program, 795
Meetings with sponsor, 748
Melt-extrusion, 628
Melting point, 18, 19, 21–2, 24, 40, 52, 161, 226, 260, 321, 327, 329, 333, 343, 395, 398, 419, 478, 504, 625, 882, 904
Meperidine Hydrochloride, 101
Metadate ER, 797
Metastable, 19, 21, 225, 397, 508
Metered dose inhaler (MDI), 417, 422, 428
Metered-dose dry powder inhalers (DPI), 416
Metered-dose liquid inhalers (MDLI), 462
Metering valve, 428–9, 432
Methadone, 101, 797
Method validation, 809, 831, 838, 876, 881, 886–8
Methylene blue, 68, 724
Methylphenidate, see Metadate ER, 797
Methylprednisolone Sodium Succinate, 102
Methylprednisone Acetate (MPA), 496, 499
Metoprolol Tartrate, 102
Metronidazole, 102
MFD (Maximal feasible dose), 912, 923
MHLW Ministerial Ordinance No. 136, 2004 on Standards for Quality Assurance for Drugs, Quasi-drugs, Cosmetics and Medical Devices, 680
MHLW Ministerial Ordinance No. 179, 2004 on Standards for Manufacturing Control and Quality Control of Drugs and Quasi-drugs, 680
MHLW Responsibilities/Major Bureau Responsibilities, 649
Micellar solutions, 52
Micelles, 38, 129, 228, 332, 359, 367, 376, 387–90, 392, 474, 477, 457, 574
Solubilization, 477
Stabilization, 474, 477
Microbial population estimation for sterilization processes, 14
Microbiology review, 746, 756
Microdermal abrasion, 612
Microemulsions, 61, 319, 331, 344, 359, 361, 367, 377, 392–3, 405, 478, 565, 600
Micromicromixing, 372–3
Microneedles, 564, 575, 601, 609–11
Micronization, 52, 125, 134, 226, 246, 367, 416, 470
Microspheres, 68, 124–5, 165, 202, 434, 441, 500, 574
Midazolam, 103, 783
Midazolam Hydrochloride syrup and injection, 783
Milliequivalence, 30–32, 43–4
Milling and size reduction, 246
Milling mean residence time, 253
Milling methods, 125–6, 129
ball mill, 248
compression mill, 248
hammer mill, 125, 246, 253
impact mill, 629
jet mill, 125, 248
jet mill fluid energy, 252
pin mill, 248
pin mill, 251
Mineral oil, 75, 230, 311, 360, 377, 382–3, 394, 443, 489, 570, 585, 598–600, 617
Minimum film formation temperature, 279
Minimum fluidization velocity, 270
Ministry of Health, Labour and Welfare, see MHLW, 649, 880–881
Misbranded, 640, 665, 685, 760, 762, 764, 878
Mitomycin, 103
Mixer impeller, 372–3
MOA, see Mechanism of action, 739, 752
Mobile film states, 258
capillary, 258–9, 270, 339, 426, 529
droplet, 258, 270–271, 282, 378, 381–2, 384, 386, 422, 425
funicular, 258–9
pendular, 258–9
MOC (Material of construction), 809, 826, 860
Model State Pharmacy Act, 698
Modified release, 38, 46, 183, 501, 619–22, 625–6, 628, 630, 633–4, 636
Modified-release systems, 620–622, 633
degradation, 621, 623
diffusion, 621–2, 626
dissolution, 621–8, 631
erosion, 621–3, 630
Moist granule strength, 259
Molarity, 32–4, 43–4
Molar heat of dissolution, 21
Molar heat of fusion, 22
Molarity, 28–30, 32–3, 43–4
Molded glass, 531
Molded starch hard-shell capsules, 326
Mole fraction, 32–3, 43–4, 605
Molecular dispersions, 61, 129, 359
Monolithic, 620, 622, 625–6, 628
Monolithic modified-release, 625
Morphine Sulfate, 104, 115–6
MRSD (Maximum recommended starting dose), 912, 932, 935
MTD (Maximum tolerance dose), 912–3, 933
Mucoadhesives, 563–4, 573, 581
ophthalmic mucoadhesives, 573
Multifunctional release, 620
Multilamellar vesicles (MLV), 170, 177, 389, 408
Multiparticulate, 620, 622, 626
Multiple emulsions, 385
Mystic EHD, 424, 426
NABP (National Association of Boards of Pharmacy), 697–8, 700, 707–8, 715
NABP Model Rules for Sterile Pharmaceuticals, 707–8
Nafcillin Sodium, 104, 115
Naltrexone Hydrochloride, 104, 115
Nanodispersions, 359, 361
Nanoemulsion, 130–131, 574
Nanomedicine, 160, 176, 376–7
Nanoparticles, 38, 52, 128–9, 130, 163, 179, 359, 365, 376–7, 387, 565, 574–5
Nanosplode™, 164, 175
Nanostructure, 53
Nanostructured Lipid Carriers, 130
Nanosuspension, 52, 129
Nanotechnology, 129, 131, 160, 359, 376–7, 499, 940
Nanotechnology Research and Development Act, 359, 376
Naratriptan Hydrochloride, 105
Nasal aerosol sprays, 172
Nasolacrimal apparatus, 562
National Association of Boards of Pharmacy (NABP), 698, 700, 720
National Center for Toxicological Research, 644
National Community Pharmacists Association, 720
National Council of State Pharmacy Association Executives, 720
National Drug Code (NDC), 713
National Environmental Policy Act, 812
National Formulary, see NF, 45, 73, 220, 420, 477, 674, 699, 805, 877–8
National Home Infusion Association, 720
National Institutes of Health (NIH), 731, 778, 782, 785, 939, 945
NCTR (United States National Center for Toxicological Research (United States)), 693
NDA (New drug application), 181–2, 189
NDA actions, 750
NDA review process, 744, 746
NDC (National Drug Code), 713
Near infrared spectroscopy, 121, 265, 272
Nebule, 427
Nebulizer formulation development, 422
Nebulizer solutions, 169, 450, 454, 456
Nebulizers, 62, 416–7, 421–5, 427
Needle-free devices, 534
Needle-free jet injector, 611
Neurontin, 753, 783
Neutral starch microspheres, 68
New Drug Application (NDA) stability assessment, 578
New drug approval accelerated, 736, 760, 773, 775
New therapies, 534, 642, 650, 773–4, 776, 778
New/ or novel excipients, 826
Newton’s law, 74
Newtonian systems, 74, 77
Newtonian viscosity in poise, 361
Nicoderm CQ, 600
Nifedipine, 53, 85, 162, 633
Niosomes, 359, 367, 389, 579, 600
Nitro-Dur, 599
No observed adverse effect level (NOAEL), 912
Nominal screen mesh number and sieve opening in micron, 316
Nominal variable, 135
Nonclinical safety studies, 739, 911–2, 914, 918
Noncorneal route, 564
Non-fiber releasing filter, 658, 693
Non-Fickian release, 163
Non-Newtonian flow, 73, 80
Nonproductive route, 564
Normality, 29, 30, 43–4, 145
NRobe™, 630
Nuclear magnetic resonance spectroscopy, 20, 22, 173
Null hypothesis, 139, 155
Number of moles, 14, 15, 24, 28, 32, 44
OBI, see Office of Business Information, 814–5, 817
Objectives & enablers for implementing PQS, 864
Occupational safety. see Industrial Hygiene, 321
Occupational exposure limits, 244
Octreotide Acetate, 169
Ocular inserts, 575
Office of Business Information (OBI), 814, 826
Office of Business Process Support (OBPS), 806
Office of Combination Products (OCP), 644, 646
Office of Compliance (OC), 757, 769
Office of Counterterrorism and Emerging Threats, 644
Office of Critical Path Programs, 644
Office of Foods, 644
Office of Generic Drugs (OGD), 753, 755–6, 769
Office of Global Regulatory Operations and Policy, 644
Office of Good Clinical Practice, 644
Office of International Programs (OIP), 644, 646
Office of Medical Products and Tobacco, 644
Office of Minority Health, 644
Office of Ombudsman, 644
Office of Orphan Product Development (OOPD), 644
Office of Pediatric Therapeutics (OPT), 644
Office of Prescription Drug Promotion (OPDP), 795
Office of Regulatory Affairs (ORA), 644, 646, 652, 883
Office of Regulatory Science and Innovation, 644, 646
Office of Special Medical Programs, 644
Office of the Chief Scientist, 644, 646
Office of Women’s Health, 644
Official of Criminal Investigation, see OCI
OGD, see Office of Generic Drugs
Oms, 603
Oil solubilization, 477
Oil stabilization, 477
Oil-in-water (O/W) emulsion, 327
Ointments, 73, 207–8, 392–3, 395–6, 401–5, 412, 526, 570–71, 577–8, 596, 718
Operational Qualification (OQ), 841–4, 847–8, 858–60, 882–3, 885, 897
Ophthalmic, 25, 68, 88, 93, 97, 172, 176, 191, 196, 208–9, 212, 369, 395–6, 404–5, 526, 561–2, 564, 566–74, 576–8, 581, 584, 669, 705, 715, 723, 739, 756
Ophthalmic applications, 25, 579
Ophthalmic product design, 561, 566–7
Oral modified-release product design, 164
Oral route of administration, 163
Oral solutions, 48, 75, 98, 101, 756
ORA-LAB 5.5, 886
Orally disintegrating tablets, 164
Zydex® fast-dissolve technology, 164
Orange Book, 700, 753
OraSolv®, 164
OraVescent® technology, 165
Ordinal variable, 135, 140, 399
Organization and personnel, 654, 706
Oriented polyamides, 284
Original submissions, 807–8
OROS system, 162
Orphan Drug Act (ODA), 773, 778–9, 783
Orphan drug regulations, 783
Orphan drugs, 648, 773, 778–9, 853
Ozurdex insert, 577
Osmolality of tears, 568
Osmolarity, 33–4, 450, 536, 568
Osmotic controlled release, 174, 632–3
Ostwald ripening, 61, 63, 362, 369, 371, 497, 508
OTC Advisory Committee Meeting, 762
OTC combination drug products, 763
OTC drug facts label, 764–5
OTC drug monograph review process, 761
OTC drugs, 760, 793, 796
Out of service equipment, 886
Out-of-specification (OOS), 851
Outsourced activities, 865–6, 897
Overdue notice letter (ONC), 817
Overlubrication, 263, 265, 340
Over-the-counter, 63, 598, 643, 665, 698, 750, 753, 760–761, 766, 781, 783, 796, 805, 878
Oxidation, 85, 112, 298, 390, 397, 475, 478, 481–4, 488–90, 495–6, 526–7, 532, 602, 887, 890, 906
Oxidated state, Ox, 482
Oxygen level, 246
PAT, see process analytical technology, 157–8, 190, 249, 256, 261, 265, 271, 273, 276, 283, 399, 436, 516–7, 523, 526, 528, 840, 850
PCTFE, see polychlorotrifluoroethylene, 290
PVdC, see polyvinylidene chloride, 284, 288
P value, 139–40, 151, 155
P&ID (pipeline and instrumentation diagram), 835, 837, 845, 860
Packaging, 25, 70, 120, 172–4, 182, 190–191, 212–3, 284, 286, 291, 535, 640, 655, 663–5, 673, 711, 870
Packaging and labeling operations [Sec. 211.130], 664
Packaging Containers and Closures, 711
Packaging material, 693, 806, 809
PakSolv® proprietary blister package, 165
Pan American Network for Drug Regulatory Harmonization (PANDRH), 650
Parametric release, 519–20, 523, 526
Parametric tests, 140
Parenteral, 25, 167, 201, 334, 360, 467, 492, 502, 505–6, 619, 739, 912
Parenteral solution scale-up, 492
Partial derivatives, 11–12
Partial pressure of constituent, 431
Pari eFlow, 424
Partial water vapor pressure in the air environment, 268
Particle engineering, 53, 432, 435–6
Particle size estimation, 140
Particle sizing, 119, 243–4, 334, 372, 385
Particulates, see injectables, 186, 365, 467, 474, 492, 532, 537, 566
Particulate control system, 152, 154
Passport thermal ablation system, 610
Pastes, 73, 319, 331, 333, 395
Patent, 640, 716, 746, 753–5, 757–9, 782
Patient counseling, 719
Patient Protection and Affordable Care Act (PPAC Act), 641, 779
PDG, 881
PediaLink, 882
Pediatric committee (PDCO), 648, 693
Pediatric Drug Development and the Orphan Drug Act Incentives, 773, 783
Pediatric drugs, 773, 780
Pediatric Research Equity Act (PREA), 641, 781–2, 786, 789–90
Pediatric research initiatives, 781
Pellets, 48, 120, 162–3, 173, 319, 328, 331, 338–9, 427, 621, 636
Penetration enhancers, 62, 441, 460, 569, 572–3, 579–80, 593–7, 605–6, 612
Penicillin contamination [Sec. 211.176], 670
Pennsaid, 596–7
Pentoxifylline, 106
Pepcid, 783
Pepsin, 168, 323
Peptide and protein degradation reactions, 490
Peptized, 364
Percent by volume or percent volume per volume, 27, 44
Percent by weight or percent weight per weight, 26–7, 44
Percent relative humidity, 286, 306
Percent weight per volume, 28, 44
Percent weight per weight, 26
Percentage of theoretical yield, 673, 693
Perfluorocarbon (PFC), 494–5, 543, 547
Performance based exposure control limits, 244
Performance indicators, 860, 865–6, 897
Performance qualification (PQ), 354, 841–3, 848, 851, 853, 883, 885
Pergolide Mesylate, 106
Permeability through selected packaging materials, 286
Permeation enhancers, 595
Permselective, 602
Perphenazine, 106, 112
Personnel qualifications, 654
Personnel responsibilities (Sec 211.28), 654, 832, 852
Personnel training, 512, 707, 861
PET; see container closure system and polyethylene terephthalate. see container closure system, 284, 288–9, 305, 643
Pharmaceutical alternatives, 46–7, 54–5, 769
Pharmaceutical and Medical Safety Bureau, 649, 689
Pharmaceutical calculations in prescription compounding, 708
Pharmaceutical compounding, 698–9, 708, 711
Pharmaceutical dosage forms, 57, 215, 264, 275, 502, 505–6, 708, 715
Pharmaceutical equivalents, 45–7, 54–5, 769
Pharmaceutical necessities, 25
Pharmaceutical quality system elements, 865
Pharmaceutical Research and Manufacturers of America (PhRMA), 650
Pharmacogenetic test, 933
Pharmacogenomics data submission to IND, 729
Pharmacologically active dose (PAD), 933, 935
Pharmacology and drug distribution, 743
Pharmacology/ toxicology Review, 743
Pharmacopoeial Comparison of Aspirin, 903
Pharmacopoeial discussion group (PDG), 881
Pharmacy Compounding Accreditation, 720
Pharmacy Compounding Accreditation Board (PCAB), 722
Pharmacy Compounding of Human Drugs (Sec. 460.200), 698–9
Phase 1 clinical studies, 732
Phase 2 clinical studies, 733
Phase 3 clinical studies, 723, 926
Phase appropriate clinical trials, 730
Phase inversion, 378, 384, 408
Phase inversion temperature (PIT), 378
Phase volume, 378–80, 382, 478, 574
Phenylpropanolamine, 53
Phenytoin Sodium, 107
Phenytoin Sodium, 330
Phosphatidylethanolamine (PE), 390–391, 479, 495
Phosphatidyglycerol (PG), 390–391
Phosphatidylinositol (PI), 390–391
Phosphatidylserine (PS), 390–391
Phospholipids, 53, 127, 134, 201–2, 389–2, 441, 481, 491, 495, 563, 596
Photochemical reactions, 85
Photostability testing, 890–891
Physical properties, see HFA-134a and HFA-227, 429
Physical stability, 20, 25, 60, 62–3, 89, 362, 370, 379, 382, 496, 509
Physical-mechanical technologies for mediated transdermal drug delivery, 601
Pilot plant scale, 897
Pin mill, 248, 251
Piping & instrumentation diagram (P&ID), 645, 835, 837, 860
Placebo (or Blank), 46, 283, 531, 897
Plackett-Burman, 230–231, 234–5, 237
Plasma impulse chemical vapor deposition, 532, 547
Plasmids, 374
Plastic deformation, 80, 247, 263–4, 271
Plastic flow, 76–7, 392
P.L.E.A.S.E. (painless laser epidermal system), 611
Plug, 259, 290–291, 319, 335–8, 501, 532, 564, 630
Plumbing [Sec. 211.48], 656
Poise, 74, 361
Poiseuille equation, 530
Polo horses, 705
Poly(EDMA-MAH), 76, 71
Polycarbophil (PC), 309, 463, 572–4
Polychlorotrifluoroethylene (PCTFE), 284
Polyester terephthalate (PET), 284, 305, 401
Polyethylene glycol (PEG), 618
Poly(lactide-co-glycolide (PLG), 547
Polymer advances, 628
Polymeric particulate matter, 128
Polymorphic crystals, 18, 24
Polyoxyxyl 35 castor oil, 53, 172, 284–5, 599, 810
Polypelex, 375
Polypropylene (PP), 90–102, 104, 106–8, 110, 213, 286, 617
Polyosorbate 80, 69, 333, 356–7, 412, 464, 480–481, 491, 500, 550, 557, 574, 582, 584
Polystyrene (PS), 284, 305
Polyvinyl acetate phthalate (PVAP), 305
Polyvinyl alcohol (PA), 618
Population standard deviation, 147
Population variance, 255
Post approval manufacturing changes, 792, 800
Postmarket commitment (PMC), 803
Postmarket requirement (PMR), 803
Postmarket requirements and commitments, 789, 803
Potato starch, 326
Potential capability, 340
Povidone, 259, 306–7, 309, 354, 356, 359, 410, 497–8, 547, 557, 584, 599, 617, 723
Powder blend material constant, 259
Powder rheometer, 81
Powdernium, 320
Powders for solution, 468, 494
Powders for suspension, 494
Power applied, 373
Power density of the material or energy absorbed, 272
Power number, 373
Power of the test, 138
compliment of β, 138
Predelivery Inspection (PDI), 837, 842
Preamble to Title 21, Subchapter C, 652
Preapproval/Request for Plant Inspection, 757
Precision, 120, 146–7, 155, 276, 526, 659, 667, 881, 888, 896–7, 905
Precommissioning, 836
Predelivery Inspection (PDI) and Factory Acceptance Test (FAT), 837, 842
Preferential hydration, 510
Prescription balances and volumetric apparatus, 708
Prescription drug advertising, 795, 798, 802
Prescription drug advertising and promotional labeling direct-to-consumers, 795, 798
Prescription Drug Marketing Act (PDMA), 641
Prescription Drug User Fee Act (PDUFA), 641, 693, 749, 783
Preservatives, 37, 322, 384, 395, 404, 424, 442, 451, 464, 468–9, 480–481, 503, 523, 537, 544, 567, 573, 578, 588, 605, 616
Pretreatment ultrasound, 607
Preventive action, 865, 867, 869, 895, 897, 900
Primary containment, 690
Primary drying, 502–3, 505–9, 511–2, 525–7
Principle of qualification (What/why/how?), 838
Principles/elements of commissioning, 835
Priority review, 746, 749, 773–6, 784, 786
Priority review policies (1997), 774–5
Probability of finding a drug particle which is equivalent to proportion of drug in the sample, 254
Probability of nonsterility (PNS), 519, 547
Probable valid biomarker, 929, 933
Probe formulation, 235, 238, 242
Process analytical technologies, 157, 348, 436–7
Process capability, 340, 840, 853, 860
Process qualification, 518, 851, 860
Process validation (PV), 181, 223, 320, 543
Processability, 121, 354
Pro-drug, 47, 52, 54, 474, 476, 543
Prodrug solubilization, 474
Prodrug stabilization, 474
Product design
decision process, 183
interrelationship between formulation
process and container closure
system design, 182
Product discontinuation, 864, 866–7, 901
Product performance qualification (PPQ),
851, 953, 860
Product problems, 795, 797
Product realization, 864, 897
Production batch, 526, 678, 731, 790, 797
Production record review [Sec. 211.192],
673
Programmable logic controller (PLC),
860
Projected area diameter, 120
Prolonged-release, 499–500, 619
Promotional labeling direct-to-consumers,
795
Propellants, 169, 195, 417, 420–422,
427–33, 450, 465
Proposed monograph/amendment, 763
Propylthiouracil, 89, 107
Prospective validation, 852, 860
Protein stabilizers, 507
Pseudoplastic flow, 76, 80, 562
Pseudoplastic materials, 76, 82
Psychrometry, 268
Public comment, 763
Public Health Emergency Medical
Countermeasures Enterprise, 943
Public’s expectations of drug regulations,
642
Pullulan, 319, 322–3, 325, 328, 355
Pullulan hard-shell capsule formulation, 325
Pulmonary delivery, 53, 126–7, 186, 435
Pulmonary delivery of drugs, 127
Pulmonary delivery of powders, 126
Pulmosphere Technology, 127, 134
Pulsatile or pulsed-release, 620
Pumping, 82, 211, 372–3, 492
Pure steam, 487
Push layer, 633
P-value, 139–40, 155, 251
PVP-Polyvinylpyrolidone, 80, 83, 237, 289,
511, 547, 584
Pyridoxine Hydrochloride, 107, 114
Pyrogens, 467, 474, 669
QbD, see Quality by Design, 194, 625,
812, 826, 832, 839, 868
QbR, see Question-based Review, 757(a),
767
QbR Quality Overall Summary Outline,
767(a)
QOS, see Quality Overall Summary,
769(a), 820–821, 826
Qualification & validation
commissioning vs. qualification, 839
current trends in qualification, 839
documentation, 840
principle of qualification, 838
(What/why/how?)
qualification model, 842, 842
qualification terminology, 841
Qualification of established (In-Use)
facilities, systems and equipment, 849
Qualification phases, 883
Qualification protocols, 842–9
design qualification (DQ), 859, 884
functional specification (FS)/functional
design specification (FDS), 843–4
installation qualification (IQ), 842,
844–7, 859, 883–4, 896
operational qualification (OQ), 842,
847–8, 860, 866, 885, 897
performance qualification (PQ), 842,
848–9, 860, 884–5, 897
qualification of established (In-Use)
facilities, systems and equipment,
849
user requirement specifications (URS),
843
Quality agreement, 826
Quality assurance in pharmaceutical
compounding, 708
Quality by design, see QbD, 194, 625, 812,
826, 832, 839, 868
Quality control and continuous quality
improvement program, 714–6
Quality control testing, 146–7
accuracy, 146
precision, 147
sensitivity, 147
Quality control unit, see QCU, 654, 673,
689, 694
Quality management, 677–8, 898
Quality manual, 865, 898
Quality objectives, 898
Quality overall summary, see QOS, 769(a),
820, 821, 826
Quality planning, 898
Quality policy, 865, 866, 871, 898
Quality risk management, 292–4, 293–4,
403, 446–50, 677–8, 863–4, 866,
867, 869, 874
Quality system, see QS, 863–8, 867,
870–875, 898
Quality systems & controls
analytical instrument qualification (AIQ),
838, 881–6, 895
inspection of pharmaceutical quality
control laboratories, 875–7
quality systems approach to CGMP
regulations, 868–74
stability testing of new drug substances
and products, 296, 889–93
validation of analytical procedures,
886–9
Quality systems approach to CGMP
regulations, 868–74
Quality systems model, 870–874
evaluation activities, 870–874
management responsibilities, 867, 870(a),
901
manufacturing operations, 872–4, 902(a)
resources, 871–2, 902(a)
Quality target product profile, 182–4,
231–2, 235, 625
Quality unit, 869, 883, 895
Quantitation limit, 888, 905(a), 918
Quantitative measures, 3
Quarantine, 655, 659, 660, 667, 694
Question-based review, see QbR, 757,
767 (a)
Question-based review for CMC
evaluations of ANDAs, 757
Rate-controlled drug delivery, 158,
160–161
Ratio scale, 135, 140
Rate controlling membrane, 598–600,
617(a)
Ratio strength, 34, 44
Recall, 680–681, 684, 687–8, 691–2,
694–5, 903
depth of recall, 691
Receipt and storage of untested
components, drug product containers,
and closures [Sec. 211.82], 659
Recommendations for In Vitro Tests,
921–2
Recommendations for In Vivo Tests, 922–3
Recommendations for investigations of
drugs for rare disease or conditions
(Sec. 525[21 USC §360aa]), 779
Recommended validation characteristics of
the various types of tests, 779
Reconciliation, 664, 672, 695, 771
Records and reports, 670, 714
Recovery, 693–5
Rectal suppositories, 397
Reduced state, Rd, 492
Reducing carbohydrates, 236
Reducing sugar, 236, 420, 491, 511
Reduction in particle size, 125
grinding, 19, 125
microcrystallization, 125
milling, 246–53, 498–9
Reference listed drug, see RLD, 753,
757–8, 770
Refuse-to-file letter issued, 746
Regulatory
worldwide, 639–51
Regulatory actions taken by the FDA,
686–7
criminal prosecution, 686
injunction, 687, 794
recall, 680–681, 684, 687–8, 691–2,
694–5, 903
seizure, 687, 695
warning letters, 652, 686, 704, 829–830
Regulatory analytical procedures, 887
Regulatory practices and guidelines,
639–687
Regulatory requirements, 829–831
Regulatory science, 644–6, 939, 945
Regulatory science initiatives, 939–44
Reynolds number, 81, 189, 373
RH, see Relative humidity, 265, 288, 
305–6, 306, 306, 356, 462, 890, 
898–9
Rheogram, 74, 76
Rheological agents, 25
Rheology, 73, 83, 409–410(a)
Ribavirin, 107
Risk analysis, 293, 426, 700, 860
Risk assessment, 293, 402, 446–7, 792, 
898, 903(a)
Risk assessment and control, 446 
aerosols, 447, 447–450 
disperse systems, 403 
tablets, assessment, 293 
tablets, control, 294
Risk Management, 292–2, 446–450, 678, 
863–74, 899, 926 
performance targets, 447, 447–50 
risk factors, 447 
risk-based approaches, 294, 757, 864, 
942 
science-based approaches, 642, 647, 840, 
868, 940–943
RLD, see reference listed drug, 753, 
757–8, 770
Robustness, 453, 868, 899, 905
Rogaine, 596
Roller compaction, 222, 224, 264–6 
Rotary soft gel die process, 345
Rotary tablet press sequence, 221
Route of administration, 183
FDA nomenclature, 194(a)
RP, see Restricted Part
RTG, see Relative Total Growth
Rules of logarithm, 3–4
Safety, 650
SADC, see Southern African Development 
Community
Safety, see industrial hygiene 
downflow booth, 244 
isolation, 244, 252 
ventilated closure, 244
Safety factor, 244, 933, 935
Safety pharmacology core battery, 916–7
Safety pharmacology studies, 914–8
animal models and other test systems
application of Good Laboratory Practice (GLP), 915
conditions under which studies are not necessary, 917
dose levels or concentrations of test substance, 916
duration of studies, 916
follow-up and supplemental safety pharmacology studies, 917
objectives and design of safety pharmacology studies, 914
safety pharmacology core battery, 916
studies on metabolites, isomers, and finished products, 916
timing of safety pharmacology studies in relation to clinical development, 917
Safety reporting requirements, 926
Safety review, 743
Safety, identity, strength, quality, and purity, see SISQP, 653, 695, 715, 871
Saline solution, 75, 92, 705
Salt solubilization, 474–6
Salt stabilization, 476
Sample size selection, 139
Sampling and testing of in-process materials and drug products [Sec. 211.110], 662
Sanitation [Sec. 211.56], 656–7
SAT, see Site acceptance test
Sativex buccal spray, 442
Scale down, 209, 493
Scale of scrutiny, 253
Scale up
blending, 257
film-coating, 283
fluid-bed granulation and drying, 271
high shear granulation, 262, 262
lyophilization, 517–8
macroemulsions, 360, 370, 377, 385–6, 404, 406
microwave vacuum granulation, 273–4
milling, 251–2
moist heat sterilization, 524
roller compaction, 265–6
semisolids, 396
solutions, 492–3
spray-drying, 401
suspension, 399
tabletting, 276–7
Scale-up and postapproval changes, 305, 396, 624
Scaling factor, 257, 273
Scopolamine patch, 590, 599
Screening and size classification, 244–5, 316(a)
Sec. 460.200, see Pharmacy Compounding of Human Drugs, 698–9
Sec. 608.400 see Compounding of Drugs for use in animals, 699, 702–4
Second falling-rate period, 268
Second Law of Thermodynamics, 17–18
Secondary containment, 690
Secondary DMF, 826
Second-order partial derivatives, 12
Section 505(j)(5)(B)(iv), 755
Sedimentation, 81, 361
Sedimentation volume, 364–5
see beck effect, 516
Segregation of particles, 131
Seizure, 687, 694–5
Selection and design of additional immunotoxicity studies, 925
Selection of batches, 891
Self organizing maps, 121, 134
Semipermeable container closure systems, 444
Semisolids, 392–6
creams, 199, 207, 395
gels, 200, 207, 227, 394, 571, 598
ointments, 101, 203, 207–8, 395, 570–571
pastes, 208, 223, 395
Sensitivity, 145, 147, 668
SEPA® (Soft enhancer of percutaneous absorption), 595, 596, 615
Sequestrants, 484, 555(a)
Serious adverse drug experience, 803
Serious disease, 785–6
Serious risk, 803, 926
Sewage and refuse [Sec. 211.50], 656
Shear, 73–4
Shear rate, 74–5, 79, 83, 396, 561
Shearing force, 74, 77, 83
Shearing rate, 76–7, 79
Shelf-life, 85–113, 117, 296, 457, 892, 896
Sherley Amendment Act, 640
Short term testing, 729
Significant change, 220, 826, 908, 909
Signs of instability, 717
Silicone oil, 69, 414, 617
Silverson mixer, 375
Simulated product, 847, 861
Simulated use tests, 404, 537
Single nucleotide polymorphism, 927, 933
Single pot process, 266, 305
fluid-bed granulation and drying, 269–72
microwave vacuum granulation and
drying, 272–4
SISQP, see safety, identity, strength,
quality, and purity, 653, 657, 676, 695
Site acceptance test, see SAT, 836–7, 860
Six-system inspection model, 869, 870
Slugging, 222, 224, 266
Small unilamellar vesicles, 170, 389–90
Small volume parenterals, 468, 532, 547
Sodium alginate, 165, 573
Soft drugs, 564, 573
Soft enhancer of percutaneous absorption
(SEPA®), 396
Soft-shell capsule, 319, 343–4, 345, 346–8
Soft-shell capsule component classes and
functions, 344
Soft-shell capsule formulation design, 344,
347
Soft-shell gelatin capsule shell composition,
345
Soft-shell starch capsule shell composition, 346
Solid dispersions, 42, 360, 396–7, 401,
405, 496
hot melt, 52, 222, 230, 309(a), 333, 351,
396–7, 628–9
spray-dried, 134, 397, 401, 409, 437, 494
suppositories, 62, 158, 205, 208, 397–9,
718
Solid microstructured transdermal system
(sMTS), 610, 615
Solid state nuclear magnetic resonance
spectroscopy, 22
Solid state physical properties and dosage
form implications
aerosols, 419–20
complex, 471
disperse systems, 366–7
injectables, 470–471
noncomplex molecules, 470–471
tablets, 226–7
Solidification (consolidation) time, 274
Solubility, 19, 21–3, 24–35, 40–2, 185–6,
362–3, 474–9
relative solubility, 22
Solubilization
complexation, 479
cosolvent, 476–7
emulsion, 478
liposome, 479
micelle, 477
oil, 477–8
prodrug, 474–6
salt, 474–6
Solution and solid state chemical properties
and dosage form implications
aerosols, 421
dispersed systems, 368
injectables, 472–3
tablets, 228
Solution calorimeter, 20
Solutions, 25–43, 50, 208
Sonophoresis, 576, 607–8
SonoPrep ultrasound system, 608
SOP, see Standard Operating Procedure,
707, 861, 899
Sotalol Hydrochloride, 107
Southern African Development
Community, see SADC, 650
Span index, 127
Special testing requirements [Sec. 211.167],
669
Specific heat of the air, 282
Specification, 659, 672, 818, 831, 842,
843–4, 875–6, 881
Specification-release, 899
Specificity, 145, 147, 155, 888, 905
Spectrophotometric experiment, 4–5
spectrophotometer, 882
Spheronization, 222, 224, 626
Spinhaler, 433–4
Spironolactone, 108
Sponsor, 733, 736, 743–4, 748, 750, 761
Sponsor—FDA milestone meetings, 733–4
end of phase 2 meeting, 734
pre-IND meeting, 733
pre-NDA meeting, 734
Spray aerosol
buccal, 166–7, 194, 438, 440
lingual, 440, 443–4
sublingual, 440, 463
Spray content uniformity (SCU), 452, 462
Spray dried dispersions (SDDs), 397
Spray drying, 397
Spray freeze drying, 126, 134, 436
Spray-dried solid dispersions, 397, 401
Spreading coefficient, 57, 63
Stability considerations in dispensing practice, see USP 〈1191〉, 699
Stability criteria and beyond-use-dating of compounded preparations 717–9
factors affecting stability, 717
guidelines to assign BUD, 718–9, 721, 725
signs of instability, 717–8
stability criteria considerations, 717
Stability indicating assay, 887, 899
Stability protocol, 296, 455, 889–93
aerosols, 456–7
capsules, 352–3
dispersed systems, 406
excipient compatibility, 231
injectables, 538–9
new drug application stability protocol tablets, 297–8
Stability storage conditions, 892
Stability studies test, 908
Stability testing [Sec. 211.166]
Stability testing of new drug substances and products, 296, 889–93
stress testing of drug substances, 889–90, 899
Stabilization
complexation, 479
cosolvent, 476–7
dispersed systems, 406
emulsion, 478
liposome, 479
micelle, 477
oil, 477–8
prodrug, 474–5
salt, 474–5
Stabilizing agents, 25, 554
Standard deviation, 122, 136, 137, 147, 155, 897
Standard error, 140, 155
Standard error of the mean, 140, 155
Standard operating practices, see SOPs, 792
Standard oxidation potential (E°), 482, 484
Standard toxicity studies, see STS, 924, 933
Starch capsules, 326, 326
Starting material, 695
State Board of Pharmacy, 700
State equation, 15, 24
State of control, 861
State regulatory authorities, 704
Statistical review, 746
Statistics, 135–148
Steady state diffusion, 593, 594
Steady-state plasma concentration (Css), 592
Steam autoclaving, 520–524, 521
Sterile injectable product design
advantages and disadvantages of injectable dosage forms, 469
adsorption, 471–2
aggregation, 375, 378, 386–8, 431, 473, 490, 532
albumin, 68, 171, 177, 377, 397, 436, 473, 490, 510
Ambisome (liposome), 479, 495–6
amphotericin B solubilization, 91, 389, 476–7, 479, 494–6
antimicrobial preservatives, 424, 464, 475, 480–481, 481, 552(a), 567, 582(a), 616(a)
antioxidants, 484–9, 554(a), 567(a)
anti-Rh, 491
attribute tests, 535–6
autooxidation, 481–3
aspirin stability, 477
Bicillin C-R (suspension), 496, 499
benzocaine stability, 477
benzocaine solubility, 478
container closure system, 531–5
cosolvent limitation and hemolysis, 33, 490
controlled release, 499–500
denaturation, 471, 490, 502–3, 507, 510
dielectric constant effect on solubility, 476–7
Depo-Medrol (suspension), 496, 499
Depo-Provera (suspension), 496, 499
Diazemul emulsion (diazepam), 494
Sterile injectable product design

(Continued)

Dipivan (propofol), 494
DOXIL (liposome), 495
doxorubicin (liposome), 66–7, 495–6
emulsions, 494–5
entacapone solubility, 475
excipients
  - antimicrobial preservatives, 552–3(a)
  - antioxidants, 554(a)
  - buffers, 551–2(a)
  - bulking agent, 555–7(a)
  - cosolvents, 548–59(a)
  - emulsifying agents, 550(a)
  - eutectic temperatures, 558(a)
  - glass collapse temperatures, 558–9(a)
  - pH adjusting agents, 551–2(a)
  - protectants, 551–2(a)
  - sequestering agents, 555(a)
  - solubilizing agents, 550(a)
  - solvents, 548–9(a)
  - surfactants, 550(a)
  - thickening agents, 550(a)
  - tonicity adjusting agents, 551–2(a)
flammability transportation
  - requirements, 488
free radicals, 482, 526
Fugizone solubility, 477
hetacillin stability, 476
homatropine stability, 477
humanized growth hormone stability, 492
injection volume for intradermal, 467
intramuscular, subcutaneous, 187, 467
Intralipid (emulsion), 480
hyperlimentation fluid, 480
large volume parenterals, 468, 487, 532,
  536, 547
liposomes, 495–6
Liposyn (emulsion hyperlimentation fluid), 480
Lupron Depot, 500
Lyophilization
  - annealing (thermal treatment), 508–9
  - cake characterization, 509–10
  - complex molecules (proteins), 442, 471,
    473, 503, 510
  - crystalline matrix, 507
  - excluded solute hypothesis, 510
  - eutectic collapse temperature, 504,
    588 (a)
  - freeze concentrate, 506–7, 588 (a)
  - freeze-dried cake, 503–18
  - glass collapse temperature, 504, 506, 558
  - process design, 510–530
  - freeze-drying process (LYO), 513–6
  - lyophilized powder for reconstitution, 501
  - preferential hydration, 510
  - hypothesis, 510
  - primary drying, 515
  - process analytical technology, 516–7
  - scale-up, 517–8
  - secondary drying, 515–6
  - product temperature (maximum available), 504
  - maximum daily dose of selected
    solubilizing agents, 480
  - metal ion sequestrants, 484, 488–9,
    555(a)
  - NPH insulins (suspensions), 496
  - NanoMill process, 499
  - natalizumab stability, 492
  - nonreducing disaccharides, 492
  - Nutropin Depot, 500
  - Oncosol (perfluorocarbon), 494
  - Ostwald ripening, 497, 508
  - oxidation-reduction reaction, 482
  - oxytocin stability, 492
  - particulate monographs, 487
  - peptide degradation reaction, 491
  - peniclozidine solubility, 478
  - Pentothal powder fill, 493
  - photodecomposition, 482
  - Plenaxi (controlled release peptide), 501
  - powder fills for reconstitution, 492, 493
  - powders for solution, 494
  - powders for suspension, 494
  - preformulation, 469
  - solid state physical properties,
    470–471
  - solution and chemical properties,
    472–3
  - protein degradation reactions, 491
  - beta-elimination, 491
  - deamidation, 491
  - dimerization, 491
  - disulfide exchange, 491
  - Maillard reaction, 236
  - oxidation, 491
  - preteolysis, 491
rabeprazole sodium stability, 477
Robaxin solubilizing agent, 480
rhizoxin solubility, 478
scale-down, 189, 492–3, 513
scale-up
	lyophilization, 518–9
	moist heat, 524
	small volume parenterals, 468, 532, 547
Soluspan (suspension), 497
sterilization
D-value, 522–3
decimal decay time, 522–3
dry heat, 494, 497, 524–5
electron beam, 528–9
F₀ (equivalent sterilization time), 523
filtration, 529–30
gamma radiation, 526–8
inactivation factor, 522, 527
moist heat, 518–24
sterility criteria, 522
process analytical technology
	dry heat sterilization, 526
gamma radiation sterilization, 528
lyophilization, 516–7
moist heat sterilization, 523–4
temperature coefficient of microbial contamination, 523
sulfites, 483, 484, 484, 489
suspensions, solid dispersions, 496–8
aspects of combination process, 497–8
in situ manufacture process, 498
valdecoxib solubility, 479
water monographs, 486–7
wet milling, 498–9
Valium solubilizing agent, 480
VePesid solubilizing agent, 480
Vfend solubilizing agent, 480
Vitalipid (Vitamins A, D, E, K₁), 494
Ziprasidone solubility, 479
Sterile injectable, 467–8
Sterile Water for Injection, 487
Sterility, 487
Sterility assurance level (SAL), 519, 547
Sterility criteria, 522
Sterility tests, 470, 523, 536, 578
Stern layer, 130, 364
Stokes law, 81, 361, 370–371, 379, 429
Storage conditions tolerances, 899
Storage statements/labeling, 893
Strain hardening, 247, 263
Strategic plan for regulatory science, 940
Stratum corneum, 166, 587, 589, 591–2, 608, 611
Stress testing, 80, 171, 889
Stress testing of drug substance, 890, 899
Strong Iodine Solution, U.S.P, 28
Lugol’s solution, 28
Strumbo-Murphy-Cochran, 527
STS, see Standard toxicity studies, 924, 944
Study ongoing, 744
Subcutaneous (SC), 187, 194, 197, 467, 476, 547, 567, 589
Subject matter experts, 840
Submicron emulsion, 574, 580
Submissions to Drug Master Files, 807–13
Subpart B—Organization and Personnel, 654
Subpart C—Buildings and Facilities, 655–7
design and construction features [Sec. 211.42], 655
Subpart D—Equipment, 657–8
Subpart E Regulations, 774–5
Subpart E—Control of Components and Drug Product Containers and Closures, 658–61
Subpart F—Production and Process Controls, 661–3
Subpart G—Packaging and Labeling Control, 663–6
Subpart H—Holding and Distribution, 667
Subpart I—Laboratory Controls, 667–70
Subpart J—Records and Reports, 670–676
Subpart K—Returned and Salvaged Drug Products, 676–7
Succinylcholine Chloride, 108
Sufentanil Citrate, 108
Sum of squares, 149–51, 153
Summary of FDA attribute tests for aerosols, 451–4
Summary report, 847–9
Summation over all the sample time points (Σ), 624
Supercritical fluid chromatography, 172
Supercritical fluid extraction of emulsions, 125–6
Superheated water spray, 521
Superporous hydrogel, 161
Supplement, 826
Supplier, 827
Suppositories, 397–9
Surface erosion, 623
Surface free energy, 59, 362, 430
Surface tension, 259, 270, 380, 529, 563, 568
Surfactant parameter, 389–90
Surfactant solubilization, 477
Surfactant stabilization, 477
Surrogate endpoint, 755, 786
Suspending, viscosity enhancing, and structural modifying agents, 409–10(a)
Suspension volume, 365
Sustained-release, 43, 53, 131, 278, 625, 629
Sweetening agents, 410(a)
Synchronized solubilizer release™, 164
Synthesis and purification, 721
Syrops, 27, 75, 205
System suitability testing, 889

TAB, see Testing, adjusting and balancing, 846

Tablets
advantages and disadvantages, 218
attribute tests, 294–6
blisters assembly, 291
blisters laminates, 291–2
blisters lidding, 290
blisters packs, 289
blisters strips, 289
blisters strip and back, 289
closures, 286–8
container closure systems, 283–92
desiccants, 286–8
diluents, 307–8(a)
direct compression, 307–8(a)
disintegrants, 312–3(a)
flow, 315(a)
glidants, 315(a)
hot-melt excipients, 309–12(a)
lubricants, 313–4(a)
wet granulation binders, 308–9(a)
wetting agents, 315–6(a)
diluents, 307–8(a)
direct compression, 307–8(a)
disintegrants, 312–3(a)
flow, 315(a)
glidants, 315(a)
hot-melt excipients, 309–12(a)
lubricants, 313–4(a)
wet granulation binders, 308–9(a)
wetting agents, 315–6(a)
excipient classes and functions, 229
excipient compatibility, 228–38
functional class approach, 232–4
glass bottles, 285
granulation, 258–74
dry roller compaction, 264–6
high shear wet granulation, 258–62
Gral high shear granulator, 261
granulation bowl size and impeller granulator, 269
process analytical technology, 265
roller compaction drawing, 264
scale up, 265–6
single–pot granulator driers, 266–74
slugging, 266
speed relationship, 262
hygroscopicity, 306, 306
oxygen scavengers, 286–8
permeability of packaging materials, 286
plastic bottles, 285
preformulation, 222–7
solid state properties, 226–7
solution and chemical properties, 228
probe tablet formulation, 239
running powder manufacturing processes, 222
advantages and disadvantages of running powder processes, 223
blending, 253–7
blend uniformity, 256
conical screw mixer, 255
V-blender, 254
film-coating, 277–84
film-coat excipient classes and functions, 280–281
film coating process, 282
process analytical technology, 283
fluid-bed, 269–74
process analytical technology, 271
scale-up, 271–2
microwave granulation drying, 272–4
excipient loss tangent, 273
process analytical technology, 273
scale-up, 273–4
milling, 246–53, 248
cone mill, 249, 250
fluid energy jet mill, 252
hammer mill, 250, 252
pin mill, 51
process analytical technology, 249–251
scale-up, 252–3
screen sizes, 316–7(a)
screen sizes, 316–7(a)
screen sizes, 316–7(a)
screen sizes, 316–7(a)
risk control, 294
screening, 245
oscillating screen, 245
stability protocol, 296–8, 297
report thresholds, 298
tableting, 274–7
compression-time profile, 275
contact time, 275
dwell time, 274
ejection time, 275
molding for freeze-dried tablet, 218
process analytical technology, 276
relationship between disintegration, dissolution and absorption, 219
residence time, 275
rotary tablet press sequence, 221
scale-up, 276–7
solidification time, 274
tablet-formation sequence, 217
Tamiflu capsules, 710, 720
Tamiflu for Oral Suspension, 710
Tamper-evident packaging, 776
Requirements for over-the-counter (OTC) human drug products [Sec. 211.132], 665
Tamper-resistant packaging requirements (TRP) for certain over-the-counter human drug products, 665
Tangent loss (microwave drying), 292–3
Tapped bulk density, 124, 127, 134
Tapped density, 331, 335, 351, 366
Taste, 399–400, 400
T-cell dependent antibody response, see TDAR, 925
Tear fluid surface tension, 568
Tear pH, 567
Technical information and content by DMF type
 type I DMF, 809
 type II DMF, 809
 type III DMF, 809–10
 type IV DMF, 810–811
 type V DMF, 811
Technology transfer, 182, 188, 863, 867, 901
Teicoplanin, 109
Temozolomide, 109
Terbutaline Sulfate, 109
Terminal velocity, 61, 361, 371
Testing and approval or rejection of components, drug product containers, and closures [Sec. 211.84], 659–660
Testing and release for distribution [Sec. 211.165], 668
Testing, adjusting and balancing, see TAB, 846
Testosterone, 109, 595, 596–7
Tetracycline Hydrochloride, 26
Texture, 78, 80, 121
Theoretical yield, 662, 693
percentage of, 693
Therapeutic equivalence evaluations, 753
Therapeutic Inequivalence Action Coordinating Committee, see TIACC, 797–8
Therapeutic inequivalence reporting, 797–8
Thermal ablation, 610–611
Thermal analysis, 20, 22
Thermal penetration enhancement, 601–2
Thermal treatment, 508–09
Thermodynamic solubility, 21, 24
Thermodynamically stable, 25, 392
Thermodynamics, 15–22
Timoptic-XE, 571
Third Law of Thermodynamics, 18, 24
Thixotropy, 76
Three dimensional printing, 630
TIACC, see Therapeutic Inequivalence Action Coordinating Committee, 795
Time limitations on production [Sec. 211.111], 663
Time to threshold, 608
Title 21 of the Code of Federal Regulations, 639
TOPAS, see container closure system and cyclic olefin polymer, 533
Total internal reflection fluorescence, 65
Total yeast and mold count, 404
Toxicology, 739–41
Transdermal product design, 587–613
advantages and disadvantages, 588
anodal delivery, 602–3
azone, 595, 596
cathodal delivery, 602–3
Cellectra electroporation system, 607
chemical penetration enhancers, 572–3, 593–4
Transdermal product design (Continued)
clonidine patch, 598, 600
Companion 80 iontophoresis system, 606
controlled heat-assisted drug delivery
system, 601–2
cumulative drug permeation, 594
Deponit, 600
diffusion coefficient, 11, 39–40, 61, 593
Dupel iontophoretic system, 606
Duragesic, 595, 600, 782
E-trans iontophoretic system, 604, 604
electropermeabilization, 606–7
patches, 598
Elgen electroporation system, 607
enhancement, 602–3, 603
estadiol, 610, 617
ethosomes, 600–601
Etrans iontophoretic system, 606
Fentanyl patch, 600
Fick’s first law, 591
frictional coefficient, 593
Habitrol, 600
hollow microstructured transdermal
system (hMTS), 610, 615
Intraject needle-free injection system, 612
Iontopatch wearable electronic disposable
drug delivery system, 606, 615
iontophoresis penetration, 602
IONSYS iontophoretic system, 606
lag time, 593–4, 601–2, 624
laser ablation permeation enhancement,
601, 611
LidoSite iontophoretic system, 606
liposomes, 73, 201–2, 389–92, 390,
495–6, 600
MacroFlux microneedles system, 610
microdermal abrasion permeation
enhancement, 612
microneedle permeation enhancement,
609–10
needle-free injector, 611–2
Nicoderm CQ, 600
nicotine patch, 600
niosomes, 389–92, 620
Nitro-Dur, 599
nitroglycerin patch, 599
Ohm’s law, 603
Passport thermal ablation system, 610
patches, 599, 615–8(a)
adhesive, 598, 616(a)
reservoir, 598
layered, 598
Penfold, 596
permeation enhancers, 595, 597, 615(a)
permselective, 602
P.L.E.A.S.E. (painless laser epidermal
system), 611
radiofrequency ablation permeation
enhancement, 611
Powderject needle-free system, 612
Rogaine, 596
scopolamine patch, 612
Soft enhancer of percutaneous
absorption (SEPA)
Solid Microstructured Transdermal
System (sMTS), 610, 615
sonophoresis permeability enhancement,
607–8
SonoPrep ultrasound system, 608
steady state flux, 591, 591–2, 594
Synera patch, 601
Testin, 596, 597
thermal penetration enhancement, 602–3
Thermal ablation permeation
enhancement, 630–631
Transderm-Nitro, 599
Transderm-Scop, 599
transfersomes, 610
Three-dimensional printing, 630
TriGrid electroporation system, 607
trolamine salicylate, 598
ultrasound permeation enhancement,
607–8
Transfer of Ownership/Agents as Holders,
816–7
Transfersomes, 610
Translational science, 939
Transmissible spongiform encephalopathy, see TSE, 323–4, 356, 420, 711, 818
Trastuzumab, 110, 115
Treatment IND, 735, 776–7, 859
Trehalose, 112, 492, 510–511
Treprostinil Sodium, 110
Triamcin®, 280, 305
Triamterene, 52
Tributyl Citrate (TBC), 280, 280, 305
Tricalcium Phosphate, 330
Triethyl Citrate (TEC), 280, 305, 356
Trifluoroacetic Acid, 167, 177
TriGrid electroporation system, 607
Trolamine Salicylate, 598
Trovaloxacin Mesylate, 110
TRP, see Tamper-resistant packaging, 766
True density, 244, 259, 265, 435
True solutions, 359
Turbohaler, 434
Trypsin, 168
Tubocurarine Chloride, 110
Tubular glass, 531
Tungsten pins, 172, 532–3
Type I DMF, 809
Type I error, α, 138–9
Type II DMF, 809
drug intermediates, substances, and material used in their preparation, 809
drug Product, 809
Type II error, β, 138
Type III: Packaging material, 809–10
Type IV: excipient, colorant, flavor, essence, or material used in their preparation, 810–811
Type of Drug Master Files
Type I, 809
Type II, 809
Type III, 809–10
Type IV, 810–811
Type V, 811
Type V: Other, 811
Types of analytical procedures, 887–8
alternate analytical procedures, 887
regulatory analytical procedures, 887
stability indicating assays, 887–8
Types of analytical procedures to be validated, 888–9
Types of clinical trials, 731–3
diagnostic trials, 731
prevention trials, 731
quality of life trials, 731
screening trials, 731
treatment trials, 731
Types of INDs, 735–6
emergency IND, 735
investigator IND, 735
treatment IND, 735
U.S. v. Johnson, the Supreme Court ruled (in 1911), 640
Ultane, 783
Ultrafine particle dispersions, 359
Ultrasonic nebulizers, 424–5
Ultrasound permeation enhancement, 607–08
UNAIDS, see Joint United Nations Programme on HIV, 780
Unilamellar vesicles (LUV), 170, 390, 408
United States Department of Agriculture.
see USDA, 639
United States Drug Enforcement Agency (United States), see DEA, 644
United States National Center for Toxicological Research (United States), see NCTR, 644
United States Pharmacopeia—National Formulary, see USP-NF, 45, 805, 878–9
United States Pharmacopeia Convention, 45, 805, 878–9
Unmet medical needs, 775–6, 787
Untitled letter, 799
Up-conversion nanoparticles, 129
UR, see user requirement, 842–3
URS, see User Required Specification, 861
Use of approved components, drug product containers, and closures [Sec. 211.86], 660
Use of vendor documentation, 840
User required specification, see URS, 861
User requirement, see UR, 842, 843
USP <1075>, see Good Compounding Practices, 705–17
USP <1191>, see Stability
Considerations in dispensing practice, 717
USP <795>, see Pharmaceutical
<table>
<thead>
<tr>
<th>Page</th>
<th>Text</th>
</tr>
</thead>
<tbody>
<tr>
<td>990</td>
<td>INDEX</td>
</tr>
</tbody>
</table>

User requirement, see UR (Continued)

- USP <797>, see Pharmaceutical Compounding–Nonsterile, 699
- Compounding—Sterile Preparations, 699, 708, 713
- USP Biological Reactivity Tests, 450, 533, 809
- USP Dosage Form Nomenclature, 207(a)–9
- USP Packaging Fabrication Materials and Closure Types, 212(a)–3
- USP Packaging Nomenclature, 209(a)–12
- USP Particulate Requirements for Injectables, 487
- USP Water Monographs, 486–7
- Utilities Commissioning, 837

V-blender, 254, 277

- Vaccine enhancement patch, 612
- Vaginal suppositories, 208
- Valid biomarker, 929–30, 932
- Validate analytical methodology, 754
- Validation master plan, see VMP, 832, 861
- Validation of analytical procedures, 887–9
  - method validation, 888–9
  - other validation considerations, 889
  - revalidation, 889
  - types of analytical procedures to be validated, 888
  - types of analytical procedures, 887–8
  - validation protocols, 888–9
- Validation team, 861
- Vaporization efficiency, 282
- Variance, 136–7, 144, 146–7
- VCPR, see veterinarian-client-patient-relationship, 703
- Vectors, 374–5
- Venlafaxine, 111
- Ventilation, air filtration, air heating and cooling [Sec. 211.46], 655–6
- Verapamil, 124, 629, 633
- Verification, 719, 836
- Veterinary compounding pharmacy, Veterinary International Conference on Harmonization. see VICH, 651
- VGDS, see voluntary genomic data submission, 930, 934
- Viable aerobic count, 404
- ViaDerm RF system, 611
- Vibrating mesh technology (VMT), 425, 465
- VICH, see Veterinary International Conference on Harmonization, see International Cooperation on Harmonization of Technical, 651
- Requirements for Registration of Veterinary Products, 647, 651
- Vinorelbine Tartrate, 111
- Viscoelasticity, 78–81
- Viscosity
  - effect of ground state, 79
  - effect of pressure, 61
  - internal friction, 73–4, 83
  - temperature, 58
- Viscosity-inducing agents, 409–410(a),
- Viscous modulus, 79
- Viscous (loss) modulus, 79
- Vitamin & mineral supplement, 705
- Vitamin A, 52
- Vitavene intravitreal injection, 577
- Vitrasert, 577
- Vitreous humor, 561–2, 564
- VMP, validation master plan, 832, 861
- Voigt unit, 78
- Volume-equivalent diameter, 120
- Voluntary genomic data submission, 930, 934
- Vortex, 373
- Waiver of Prescription Drug User Fee Act, 783
- Warehousing procedures [Sec. 211.142], 667
- Warning Letter, see WL
  - CIN-07–28792–06, 698, 702
  - DEN # 07–02FDA, 702
  - KAN-2005–04, 704
- WL, see Warning Letter
- WL: CIN-10–107809–16, 704
- Washing and toilet facilities [Sec. 211.52], 656
- Water (USP), 486–7
  - pure steam, 786
  - purified water, 786
  - sterile water for injection, 487
  - water for injection, 786
- Water glass, 532
- Water of hydration, 31, 267
Water substitute concept, 511
Water vapor, 268, 282, 286–7, 305
Water vapor pressure-temperature profile, 552
Water vapor transmission rate, 287, 305
Water-in-oil (W/O) emulsion, 195, 208, 377, 379, 384–5, 408
WEDD (wearable electronic disposable drug delivery), 606
Weight size distribution, 124
Wet bulb, 268, 271, 282
Wet bulb temperature, 268, 271, 282
Wet extrusion, 222, 224, 271
Wet granulation, 22, 47, 222–4, 258–62
Wet granulation binders, 230, 308–9(a)
Wetting agents, 229, 230, 315(a), 369, 567, 585(a)
Wetting time, 151, 155
WHO, see World Health Organization, 647, 649, 696
Williams-Landell-Ferry, 89, 117
Withdrawal time, 703–4, 716
Work done by the mixer, 373
Work hardening, 247, 247, 265
Work of adhesion, 57, 59
Work of an isothermal expansion of an ideal gas, 15, 24
Work of cohesion, 218, 230
Worldwide regulatory agencies, 639–51
Written prescription drug interaction guidelines, 708
Written procedures; deviations [Sec. 211.100], 661
Xcelodose, 320
X-ray diffraction, 22, 24, 528–9
Yield value, 76, 562
Z value, 522–4, 547
Zero-shear rate viscosity, 79
Zeroth Law of Thermodynamics, 15, 24
Zeta potential, 62, 130, 364
electric double layer, 130, 364
Zidovudine, 773
Zolpidem oral spray, 442